<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1401" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1401/" /><meta name="ncbi_pagename" content="Fanconi Anemia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Fanconi Anemia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Fanconi Anemia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/03/08" /><meta name="citation_author" content="Parinda A Mehta" /><meta name="citation_author" content="Jakub Tolar" /><meta name="citation_pmid" content="20301575" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/" /><meta name="citation_keywords" content="Fanconi Pancytopenia" /><meta name="citation_keywords" content="Fanconi Pancytopenia" /><meta name="citation_keywords" content="Breast cancer type 2 susceptibility protein" /><meta name="citation_keywords" content="DNA repair endonuclease XPF" /><meta name="citation_keywords" content="DNA repair protein RAD51 homolog 1" /><meta name="citation_keywords" content="DNA repair protein RAD51 homolog 3" /><meta name="citation_keywords" content="DNA repair protein XRCC2" /><meta name="citation_keywords" content="E3 ubiquitin-protein ligase FANCL" /><meta name="citation_keywords" content="E3 ubiquitin-protein ligase RFWD3" /><meta name="citation_keywords" content="Fanconi anemia group A protein" /><meta name="citation_keywords" content="Fanconi anemia group B protein" /><meta name="citation_keywords" content="Fanconi anemia group C protein" /><meta name="citation_keywords" content="Fanconi anemia group D2 protein" /><meta name="citation_keywords" content="Fanconi anemia group E protein" /><meta name="citation_keywords" content="Fanconi anemia group F protein" /><meta name="citation_keywords" content="Fanconi anemia group G protein" /><meta name="citation_keywords" content="Fanconi anemia group I protein" /><meta name="citation_keywords" content="Fanconi anemia group J protein" /><meta name="citation_keywords" content="Fanconi anemia group M protein" /><meta name="citation_keywords" content="Mitotic spindle assembly checkpoint protein MAD2B" /><meta name="citation_keywords" content="Partner and localizer of BRCA2" /><meta name="citation_keywords" content="Structure-specific endonuclease subunit SLX4" /><meta name="citation_keywords" content="Ubiquitin-conjugating enzyme E2 T" /><meta name="citation_keywords" content="BRCA2" /><meta name="citation_keywords" content="BRIP1" /><meta name="citation_keywords" content="ERCC4" /><meta name="citation_keywords" content="FANCA" /><meta name="citation_keywords" content="FANCB" /><meta name="citation_keywords" content="FANCC" /><meta name="citation_keywords" content="FANCD2" /><meta name="citation_keywords" content="FANCE" /><meta name="citation_keywords" content="FANCF" /><meta name="citation_keywords" content="FANCG" /><meta name="citation_keywords" content="FANCI" /><meta name="citation_keywords" content="FANCL" /><meta name="citation_keywords" content="FANCM" /><meta name="citation_keywords" content="MAD2L2" /><meta name="citation_keywords" content="PALB2" /><meta name="citation_keywords" content="RAD51" /><meta name="citation_keywords" content="RAD51C" /><meta name="citation_keywords" content="RFWD3" /><meta name="citation_keywords" content="SLX4" /><meta name="citation_keywords" content="UBE2T" /><meta name="citation_keywords" content="XRCC2" /><meta name="citation_keywords" content="Fanconi Anemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Fanconi Anemia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Parinda A Mehta" /><meta name="DC.Contributor" content="Jakub Tolar" /><meta name="DC.Date" content="2018/03/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/" /><meta name="description" content="Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, gastrointestinal tract, and genitourinary tract – are more common in individuals with FA." /><meta name="og:title" content="Fanconi Anemia" /><meta name="og:type" content="book" /><meta name="og:description" content="Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, gastrointestinal tract, and genitourinary tract – are more common in individuals with FA." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/fa/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1401/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D684DE040442100000000056B01FA.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1401_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1401_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/porphyria-ct/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fahn/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1401_"><span class="title" itemprop="name">Fanconi Anemia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Fanconi Pancytopenia</div><p class="contrib-group"><span itemprop="author">Parinda A Mehta</span>, MD and <span itemprop="author">Jakub Tolar</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1401_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1401_ai__"><div class="contrib half_rhythm"><span itemprop="author">Parinda A Mehta</span>, MD<div class="affiliation small">Professor, Division of Bone Marrow Transplantation and Immune Deficiency<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@athem.adnirap" class="oemail">gro.cmhcc@athem.adnirap</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jakub Tolar</span>, MD, PhD<div class="affiliation small">Professor, Division of Blood and Marrow Transplantation<br />Stem Cell Institute<br />University of Minnesota<br />Minneapolis, Minnesota</div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 14, 2002</span>; Last Revision: <span itemprop="dateModified">March 8, 2018</span>.</p><p><em>Estimated reading time: 51 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fa.Summary" itemprop="description"><h2 id="_fa_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors &#x02013; particularly of the head and neck, skin, gastrointestinal tract, and genitourinary tract &#x02013; are more common in individuals with FA.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of FA is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage and radial forms on <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> testing of lymphocytes with diepoxybutane (DEB) and mitomycin C (MMC). The diagnosis is confirmed by identification of one of the following:</p><ul><li class="half_rhythm"><div>Biallelic pathogenic variants in one of the 19 genes known to cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RAD51</i>, known to cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> FA</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FANCB</i>, known to cause <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> FA</div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA; administration of G-CSF improves the neutrophil count in some; hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA, but the high risk for solid tumors remains and may even be increased in those undergoing HSCT. All these treatments have potential significant toxicity. Early detection and surgical removal remains the mainstay of therapy for solid tumors.</p><p><i>Prevention of primary manifestations:</i> Human papilloma virus (HPV) vaccination to reduce the risk of gynecologic cancer in females, and possibly reduce the risk of oral cancer in all individuals.</p><p><i>Prevention of secondary complications:</i> T-cell depletion of the donor graft to minimize the risk of graft vs host disease; conditioning regimen without radiation prior to HSCT to reduce the risk of subsequent solid tumors.</p><p><i>Surveillance:</i> Annual evaluation with a multidisciplinary team including an endocrinologist; monitoring for evidence of bone marrow failure (regular blood counts; at least annual bone marrow aspirate/biopsy to evaluate morphology, cellularity, and cytogenetics); for those receiving androgen therapy, monitoring liver function tests and regular ultrasound examination of the liver; monitoring for solid tumors (oropharyngeal and gynecologic examinations).</p><p><i>Agents/circumstances to avoid:</i> Transfusions of red cells or platelets for persons who are candidates for HSCT; family members as blood donors if HSCT is being considered; blood products that are not filtered (leukodepleted) or irradiated; toxic agents that have been implicated in tumorigenesis; unsafe sex practices, which increase the risk of HPV-associated malignancy; radiographic studies solely for the purpose of surveillance (i.e., in the absence of clinical indications).</p><p><i>Evaluation of relatives at risk:</i> DEB/MMC testing or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the family-specific pathogenic variants are known) of all sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> for early diagnosis, treatment, and monitoring for physical abnormalities, bone marrow failure, and related cancers.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Fanconi anemia (FA) can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (<i>RAD51</i>-related FA), or an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner (<i>FANCB</i>-related FA).</p><p><i>Autosomal recessive FA:</i> Each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of inheriting one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of inheriting both normal alleles and not being a carrier. Carriers (heterozygotes) for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA are asymptomatic.</p><p><i>Autosomal dominant FA:</i> Given that all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with <i>RAD51</i>-related FA reported to date have the disorder as a result of a <i>de novo RAD51</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to other family members is presumed to be low.</p><p><i><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> FA:</i> For <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> females the chance of transmitting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy is 50%; males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be carriers and will usually not be affected.</p><p>Carrier testing for at-risk relatives (for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> FA) and prenatal testing for pregnancies at increased risk are possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known.</p></div></div><div id="fa.Diagnosis"><h2 id="_fa_Diagnosis_">Diagnosis</h2><p>Recommendations for diagnosis were agreed upon at a 2013 consensus conference (see <a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anemia: Guidelines for Diagnosis and Management</a>).</p><div id="fa.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Fanconi anemia (FA) <b>should be suspected</b> in individuals with the following clinical and laboratory features.</p><p><b>Physical features</b> (in ~75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons)</p><ul><li class="half_rhythm"><div>Prenatal and/or postnatal short stature</div></li><li class="half_rhythm"><div>Abnormal skin pigmentation (e.g., caf&#x000e9; au lait macules, hypopigmentation)</div></li><li class="half_rhythm"><div>Skeletal malformations (e.g., hypoplastic thumb, hypoplastic radius)</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Ophthalmic anomalies</div></li><li class="half_rhythm"><div>Genitourinary tract anomalies</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div>Macrocytosis</div></li><li class="half_rhythm"><div>Increased fetal hemoglobin (often precedes anemia)</div></li><li class="half_rhythm"><div>Cytopenia (especially thrombocytopenia, leukopenia and neutropenia)</div></li></ul><p><b>Pathology findings</b></p><ul><li class="half_rhythm"><div>Progressive bone marrow failure</div></li><li class="half_rhythm"><div>Adult-onset aplastic anemia</div></li><li class="half_rhythm"><div>Myelodysplastic syndrome (MDS)</div></li><li class="half_rhythm"><div>Acute myelogenous leukemia (AML)</div></li><li class="half_rhythm"><div>Early-onset solid tumors (e.g., squamous cell carcinomas of the head and neck, esophagus, and vulva; cervical cancer; and liver tumors)</div></li><li class="half_rhythm"><div>Inordinate toxicities from chemotherapy or radiation</div></li></ul></div><div id="fa.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of FA <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following findings:</p><ul><li class="half_rhythm"><div class="half_rhythm">Increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage and radial forms on <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> testing of lymphocytes with diepoxybutane (DEB) and mitomycin C (MMC)</div><div class="half_rhythm">Note: (1) The background rate of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage in control chromosomes is more variable with MMC; thus, some centers use DEB while other centers use both DEB and MMC. (2) If results of lymphocyte testing are normal or inconclusive and <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> is suspected, testing can be performed on an alternative cell type, such as skin fibroblasts. See <a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anemia: Guidelines for Diagnosis and Management</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the 18 genes known to cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA, or a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RAD51</i> known to cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> FA, or a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> pathogenic variant in <i>FANCB</i>, known to cause <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> FA (see <a class="figpopup" href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi/?report=objectonly" target="object" rid-figpopup="figfaTmoleculargeneticsoffanconianemi" rid-ob="figobfaTmoleculargeneticsoffanconianemi">Table 1</a>)</div></li></ul><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>FANCA</i> can be performed first, followed by gene-targeted <i>FANCA</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes the genes in <a class="figpopup" href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi/?report=objectonly" target="object" rid-figpopup="figfaTmoleculargeneticsoffanconianemi" rid-ob="figobfaTmoleculargeneticsoffanconianemi">Table 1a</a> and <a class="figpopup" href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi_1/?report=objectonly" target="object" rid-figpopup="figfaTmoleculargeneticsoffanconianemi1" rid-ob="figobfaTmoleculargeneticsoffanconianemi1">Table 1b</a> and other genes of interest (see <a href="#fa.Differential_Diagnosis">Differential Diagnosis</a>) may be considered next if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing does not identify a <i>FANCA</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting identification of pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of Fanconi anemia. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="fa.T.molecular_genetics_of_fanconi_anemi" class="table"><h3><span class="label">Table 1a. </span></h3><div class="caption"><p>Molecular Genetics of Fanconi Anemia: Most Common Genetic Causes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.molecular_genetics_of_fanconi_anemi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" style="text-align:left;vertical-align:middle;">Complementation Group&#x000a0;<sup>3</sup></th><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" style="text-align:left;vertical-align:middle;">% of FA Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>4</sup></th><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>5</sup> Detected by Method</th></tr><tr><th headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4" id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>6</sup></th><th headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4" id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></th></tr></thead><tbody><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA2</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-D1</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~3%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRIP1</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-J</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCA</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-A</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-70%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~60%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;20 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variants reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCB</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-B</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variants reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCC</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-C</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~14%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Several <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variants reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCD2</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-D2</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~3%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variants reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCE</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-E</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~3%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCF</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-F</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variants reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCG</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-G</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCI</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-I</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_4 hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> variant reported; see <a href="/books/NBK1401/#fa.molgen.TA">HGMD</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Pathogenic variants of any one of the genes included in this table account for &#x0003e;1% of FA</p></div></dd><dt>1. </dt><dd><div id="fa.TF.1a.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="fa.TF.1a.2"><p class="no_margin">See <a href="/books/NBK1401/#fa.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="fa.TF.1a.3"><p class="no_margin">Prior to identification of the genes, complementation groups were defined based on somatic cell-based methods. While complementation analysis testing has been supplanted by multigene panels; this terminology continues to be used in some contexts.</p></div></dd><dt>4. </dt><dd><div id="fa.TF.1a.4"><p class="no_margin"><a class="bk_pop" href="#fa.REF.shimamura.2010.101">Shimamura &#x00026; Alter [2010]</a></p></div></dd><dt>5. </dt><dd><div id="fa.TF.1a.5"><p class="no_margin">See <a href="#fa.Molecular_Genetics">Molecular Genetics</a> for information on pathogenic variants detected.</p></div></dd><dt>6. </dt><dd><div id="fa.TF.1a.6"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>7. </dt><dd><div id="fa.TF.1a.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div><div id="fa.T.molecular_genetics_of_fanconi_anemi_1" class="table"><h3><span class="label">Table 1b. </span></h3><div class="caption"><p>Molecular Genetics of Fanconi Anemia: Less Common Genetic Causes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.molecular_genetics_of_fanconi_anemi_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2,&#x000a0;3</sup></th><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complementation Group&#x000a0;<sup>4</sup></th><th id="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ERCC4</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-Q</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 individuals w/FA &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ERCC4</i> pathogenic variants reported [<a class="bk_pop" href="#fa.REF.bogliolo.2013.800">Bogliolo et al 2013</a>]; functional studies of <i>ERCC4</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants reported by <a class="bk_pop" href="#fa.REF.osorio.2013.1615">Osorio et al [2013]</a></td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCL</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-L</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13 <i>FANCL</i> pathogenic variants reported [<a class="bk_pop" href="#fa.REF.chandrasekharappa.2013.e138">Chandrasekharappa et al 2013</a>, <a class="bk_pop" href="#fa.REF.nicchia.2015.1003">Nicchia et al 2015</a>, <a class="bk_pop" href="#fa.REF.vetro.2015.562">Vetro et al 2015</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCM</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-M</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assignment of a formal complementation group for persons w/<i>FANCM</i> pathogenic variants still controversial as only 1 reference family/cell line has been identified &#x00026; that cell line has been determined to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in both <i>FANCA</i> &#x00026; <i>FANCM</i>. Of note, under experimental conditions specific knockdown of <i>FANCM</i> alone results in an FA <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#fa.REF.singh.2009.174">Singh et al 2009</a>].</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAD2L2</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-V</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual w/<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants reported [<a class="bk_pop" href="#fa.REF.bluteau.2016.3580">Bluteau et al 2016</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PALB2</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-N</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14 <i>PALB2</i> pathogenic variants reported incl a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 1-10 [<a class="bk_pop" href="#fa.REF.reid.2007.162">Reid et al 2007</a>, <a class="bk_pop" href="#fa.REF.xia.2007.159">Xia et al 2007</a>, <a class="bk_pop" href="#fa.REF.byrd.2016.e1005945">Byrd et al 2016</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAD51</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-R</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 individuals w/features of FA &#x00026; a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>RAD51</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> reported [<a class="bk_pop" href="#fa.REF.ameziane.2015.8829">Ameziane et al 2015</a>, <a class="bk_pop" href="#fa.REF.wang.2015.478">Wang et al 2015</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAD51C</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-O</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assignment of a formal complementation group for persons w/<i>RAD51C</i> pathogenic variants still controversial as only 1 reference <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> family identified [<a class="bk_pop" href="#fa.REF.vaz.2010.406">Vaz et al 2010</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RFWD3</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-W</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual w/features of FA &#x00026; <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants in <i>RFWD3</i> reported [<a class="bk_pop" href="#fa.REF.knies.2017.3013">Knies et al 2017</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLX4</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-P</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assignment of a formal complementation group for persons w/<i>SLX4</i> pathogenic variants still controversial as only a handful of reference families have been identified &#x00026; <i>SLX4</i> biology falls outside previously characterized FA proteins [<a class="bk_pop" href="#fa.REF.kim.2011.142">Kim et al 2011</a>, <a class="bk_pop" href="#fa.REF.stoepker.2011.138">Stoepker et al 2011</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UBE2T</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-T</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual w/<a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UBE2T</i> pathogenic variants incl a large paternal <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> &#x00026; a maternal <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> reported [<a class="bk_pop" href="#fa.REF.rickman.2015.35">Rickman et al 2015</a>, <a class="bk_pop" href="#fa.REF.virts.2015.5093">Virts et al 2015</a>]</td></tr><tr><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XRCC2</i></td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-U</td><td headers="hd_h_fa.T.molecular_genetics_of_fanconi_anemi_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual w/<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants reported [<a class="bk_pop" href="#fa.REF.park.2016.672">Park et al 2016</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Pathogenic variants of any one of the genes listed in this table are reported in only a few families (i.e., &#x0003c;1% of FA)</p></div></dd><dt>1. </dt><dd><div id="fa.TF.1b.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="fa.TF.1b.2"><p class="no_margin">See <a href="/books/NBK1401/#fa.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="fa.TF.1b.3"><p class="no_margin">Genes are not described in detail in <a href="#fa.Molecular_Genetics">Molecular Genetics</a> but may be included <a href="/books/NBK1401/bin/fa-less_common_genes.pdf">here</a> (pdf).</p></div></dd><dt>4. </dt><dd><div id="fa.TF.1b.4"><p class="no_margin">Prior to identification of the genes, complementation groups were defined based on somatic cell-based methods this terminology continues to be used in some contexts.</p></div></dd></dl></div></div></div></div></div><div id="fa.Clinical_Characteristics"><h2 id="_fa_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fa.Clinical_Description"><h3>Clinical Description</h3><p>The primary clinical features of Fanconi anemia (FA) include physical features, progressive bone marrow failure manifest as pancytopenia, and cancer susceptibility; however, some individuals with FA have neither physical abnormalities nor bone marrow failure.</p><p><b>Physical features</b> occur in approximately 75% of individuals with FA.</p><ul><li class="half_rhythm"><div>Growth deficiency: prenatal and/or postnatal short stature, low birth weight</div></li><li class="half_rhythm"><div>Abnormal skin pigmentation (40%): generalized hyperpigmentation; caf&#x000e9; au lait macules, hypopigmentation</div></li><li class="half_rhythm"><div>Skeletal malformations of upper limbs, unilateral or bilateral (35%):</div><ul><li class="half_rhythm"><div>Thumbs (35%): absent, hypoplastic, bifid, duplicated, triphalangeal, long, proximally placed</div></li><li class="half_rhythm"><div>Radii (7%): absent or hypoplastic (only with abnormal thumbs), absent or weak pulse</div></li><li class="half_rhythm"><div>Hands (5%): flat thenar eminence, absent first metacarpal, clinodactyly, polydactyly</div></li><li class="half_rhythm"><div>Ulnae (1%): dysplastic, short</div></li></ul></li><li class="half_rhythm"><div>Skeletal malformations of lower limbs (5%)</div><ul><li class="half_rhythm"><div>Syndactyly, abnormal toes, club feet</div></li><li class="half_rhythm"><div>Congenital hip dislocation</div></li></ul></li><li class="half_rhythm"><div>Microcephaly (20%)</div></li><li class="half_rhythm"><div>Ophthalmic (20%): microphthalmia, cataracts, astigmatism, strabismus, epicanthal folds, hypotelorism, hypertelorism, ptosis</div></li><li class="half_rhythm"><div>Genitourinary tract anomalies:</div><ul><li class="half_rhythm"><div class="half_rhythm">Renal (20%): horseshoe, ectopic, pelvic, hypoplastic, dysplastic, or absent kidney; hydronephrosis or hydroureter</div></li><li class="half_rhythm"><div class="half_rhythm">Males (25%). Hypospadias, micropenis, cryptorchidism, anorchia, hypo- or azoospermia, reduced fertility</div></li><li class="half_rhythm"><div class="half_rhythm">Females (2%). bicornuate or uterus malposition, small ovaries</div><div class="half_rhythm">Note: Pregnancy is possible in females, whether or not they have undergone hematopoietic stem cell transplantation.</div></li></ul></li><li class="half_rhythm"><div>Endocrine: hypothyroidism, glucose/insulin abnormalities</div></li><li class="half_rhythm"><div>Hearing loss, usually conductive secondary to middle ear bony anomalies; abnormal ear shape: dysplastic, narrow ear canal, abnormal pinna (10%)</div></li><li class="half_rhythm"><div>Congenital heart defect (6%): patent ductus arteriosus, atrial septal defect, ventricular septal defect, coarctation of the aorta, truncus arteriosus, situs inversus</div></li><li class="half_rhythm"><div>Gastrointestinal (5%): esophageal, duodenal, or jejunal atresia, imperforate anus, tracheoesophageal fistula, annular pancreas, malrotation</div></li><li class="half_rhythm"><div>Central nervous system (3%): small pituitary, pituitary stalk interruption syndrome, absent corpus callosum, cerebellar hypoplasia, hydrocephalus, dilated ventricles</div></li><li class="half_rhythm"><div>Other</div><ul><li class="half_rhythm"><div>Facial features (2%): triangular, micrognathia, mid-face hypoplasia</div></li><li class="half_rhythm"><div>Spine anomalies (2%): spina bifida, scoliosis, hemivertebrae, rib anomalies, coccygeal aplasia</div></li><li class="half_rhythm"><div>Neck anomalies (1%): Sprengel deformity, Klippel-Feil anomaly, short or webbed neck, low hairline</div></li></ul></li></ul><p>Note: Percentages are calculated from 2,000 individuals reported in the literature from 1927 to 2009. Frequencies are approximate, since many reports did not mention physical descriptions.</p><p><b>Developmental delay</b> and/or intellectual disability (10%)</p><p><b>Bone marrow failure.</b> The age of onset is highly variable, even among sibs. An analysis of 754 individuals with pathogenic variants in <i>FANCA</i>, <i>FANCC</i>, and <i>FANCG</i> identified an average age of onset of 7.6 years. Rarely, bone marrow failure can present in infants and small children [<a class="bk_pop" href="#fa.REF.shimamura.2010.101">Shimamura &#x00026; Alter 2010</a>]. The risk of developing any hematologic abnormality is 90% by age 40 years [<a class="bk_pop" href="#fa.REF.kutler.2003.1249">Kutler et al 2003</a>].</p><ul><li class="half_rhythm"><div>Thrombocytopenia or leukopenia usually precede anemia. These are commonly associated with macrocytosis and elevated fetal hemoglobin.</div></li><li class="half_rhythm"><div>Pancytopenia generally worsens over time.</div></li><li class="half_rhythm"><div>Sweet syndrome (neutrophilic skin infiltration) was associated with progression of hematologic disease in six out of seven individuals with FA [<a class="bk_pop" href="#fa.REF.giulino.2011.278">Giulino et al 2011</a>].</div></li><li class="half_rhythm"><div>The severity of bone marrow failure can be classified by the degree of cytopenia(s) (<a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fanca_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfancapathogenicvariants" rid-ob="figobfaTselectedfancapathogenicvariants">Table 3</a>). Importantly, to meet these criteria for marrow failure, the cytopenias must be persistent and unexplained by other causes.</div></li></ul><div id="fa.T.severity_of_bone_marrow_failure_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Severity of Bone Marrow Failure in Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.severity_of_bone_marrow_failure_in_lrgtbl__"><table><thead><tr><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate</th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Absolute neutrophil count (ANC)</b></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1,500/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;500/mm<sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Platelet count</b></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">150,000-50,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;50,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;30,000/mm<sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hemoglobin (Hb) level</b></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;8 g/dL</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;8 g/dL</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;8 g/dL</td></tr></tbody></table></div></div><p><b>Cancer susceptibility.</b> The relative risk for acute myelogenous leukemia (AML) is increased approximately 500-fold [<a class="bk_pop" href="#fa.REF.rosenberg.2008.511">Rosenberg et al 2008</a>, <a class="bk_pop" href="#fa.REF.alter.2010.179">Alter et al 2010</a>, <a class="bk_pop" href="#fa.REF.tamary.2010.1300">Tamary et al 2010</a>]. In a competing risk analysis of the combined cohorts, the cumulative incidence of AML was 13% by age 50 years, with most individuals diagnosed between ages 15 and 35 years.</p><p>An increased risk of developing myelodysplastic syndrome (MDS)/AML is associated with <a class="def" href="/books/n/gene/glossary/def-item/monosomy/">monosomy</a> 7 and most 7q deletions. Clonal amplifications of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 3q26-q29 were reported in association with an increased risk of progression to MDS/AML [<a class="bk_pop" href="#fa.REF.neitzel.2007">Neitzel et al 2007</a>, <a class="bk_pop" href="#fa.REF.mehta.2010.180">Mehta et al 2010</a>].</p><p><b>Solid tumors</b> may be the first manifestation of FA in individuals who have no birth defects and have not experienced bone marrow failure.</p><ul><li class="half_rhythm"><div>Head and neck squamous cell carcinomas (HNSCCs) are the most common solid tumor in individuals with FA. The incidence is 500- to 700-fold higher than in the general population. The HNSCCs in FA show distinct differences compared to HNSCCs seen in the general population. HNSCCs:</div><ul><li class="half_rhythm"><div>Occur at an earlier age (20-40 years) than in the general population;</div></li><li class="half_rhythm"><div>Are most commonly in the the oral cavity (e.g., tongue);</div></li><li class="half_rhythm"><div>Present at an advanced stage;</div></li><li class="half_rhythm"><div>Respond poorly to therapy.</div></li></ul></li><li class="half_rhythm"><div>Individuals with FA are at increased risk for second primary cancers in the skin and genitourinary tract. The pattern of second primaries resembles that observed in HPV-associated HNSCC in the general population [<a class="bk_pop" href="#fa.REF.morris.2011.739">Morris et al 2011</a>].</div></li><li class="half_rhythm"><div>Individuals with FA receiving androgen treatment for bone marrow failure are also at increased risk for liver tumors.</div></li></ul></div><div id="fa.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p><b><i>BRCA2</i>.</b> Biallelic pathogenic variants in <i>BRCA2</i> are associated with early-onset acute leukemia and solid tumors [<a class="bk_pop" href="#fa.REF.hirsch.2004.2554">Hirsch et al 2004</a>, <a class="bk_pop" href="#fa.REF.wagner.2004.3226">Wagner et al 2004</a>, <a class="bk_pop" href="#fa.REF.myers.2012.462">Myers et al 2012</a>]. The cumulative probability of any malignancy was 97% by age six years, including AML, medulloblastoma, and Wilms tumor [<a class="bk_pop" href="#fa.REF.alter.2007.1">Alter et al 2007</a>].</p><p><b><i>FANCG</i>.</b> Pathogenic variants in <i>FANCG</i> may be associated with severe marrow failure and a higher incidence of leukemia compared to <i>FANCC</i> [<a class="bk_pop" href="#fa.REF.faivre.2000.4064">Faivre et al 2000</a>].</p><p><b><i>PALB2.</i></b> Solid tumors (e.g., medulloblastoma, Wilms tumor) are associated with <i>PALB2</i> pathogenic variants [<a class="bk_pop" href="#fa.REF.reid.2007.162">Reid et al 2007</a>].</p></div><div id="fa.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The clinical spectrum of FA remains heterogenous. There are no clearcut <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> [<a class="bk_pop" href="#fa.REF.neveling.2009.73">Neveling et al 2009</a>]. In general, <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants lead to a more severe phenotype (e.g., <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies, early-onset bone marrow failure, and MDS/AML) than <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> variants.</p><p><b><i>BRCA2</i>.</b> All persons with an IVS7 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRCA2</i> developed AML by age three years; those with other <i>BRCA2</i> pathogenic variants who developed AML did so by age six years [<a class="bk_pop" href="#fa.REF.alter.2006.446">Alter 2006</a>].</p><p><b><i>FANCA</i>.</b> Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> pathogenic variants in <i>FANCA</i> may have earlier onset of anemia and higher incidence of leukemia than individuals with pathogenic variants that permit production of an abnormal FANCA protein [<a class="bk_pop" href="#fa.REF.faivre.2000.4064">Faivre et al 2000</a>].</p><p><b><i>FANCC</i></b></p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfanccpathogenicvariants" rid-ob="figobfaTselectedfanccpathogenicvariants">c.456+4A&#x0003e;T</a>, <a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfanccpathogenicvariants" rid-ob="figobfaTselectedfanccpathogenicvariants">p.Arg548Ter</a>, and <a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfanccpathogenicvariants" rid-ob="figobfaTselectedfanccpathogenicvariants">p.Leu554Pro</a> are associated with earlier onset of hematologic abnormalities and more severe <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies than other pathogenic variants, such as del22G [<a class="bk_pop" href="#fa.REF.faivre.2005.55">Faivre et al 2005</a>].</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfanccpathogenicvariants" rid-ob="figobfaTselectedfanccpathogenicvariants">p.Asp23IlefsTer23</a> and <a class="figpopup" href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figfaTselectedfanccpathogenicvariants" rid-ob="figobfaTselectedfanccpathogenicvariants">p.Gln13Ter</a> are associated with a lower risk for <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies and later progression to bone marrow failure [<a class="bk_pop" href="#fa.REF.yamashita.1996.4424">Yamashita et al 1996</a>, <a class="bk_pop" href="#fa.REF.gillio.1997.105">Gillio et al 1997</a>].</div></li><li class="half_rhythm"><div>c.456+4A&#x0003e;T results in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in Japanese individuals than in <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> individuals [<a class="bk_pop" href="#fa.REF.futaki.2000.1493">Futaki et al 2000</a>].</div></li></ul></div><div id="fa.Prevalence"><h3>Prevalence</h3><p>Fanconi anemia (FA) is the most common genetic cause of aplastic anemia and one of the most common genetic causes of hematologic malignancy.</p><p>The ratio of males to females is 1.2:1 (p&#x0003c;0.001 vs expected 1.00).</p><p><a class="bk_pop" href="#fa.REF.rosenberg.2011.1877">Rosenberg et al [2011]</a> showed higher <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> rates for FA than previously reported. Carrier frequency was 1:181 in North Americans and 1:93 in Israel. Specific populations have founder variants with increased carrier frequencies (&#x0003c;1:100), including Ashkenazi Jews (<i>FANCC</i>, <i>BRCA2</i>), northern Europeans (<i>FANCC</i>), Afrikaners (<i>FANCA</i>), sub-Saharan Blacks (<i>FANCG</i>), Spanish Gypsies (<i>FANCA</i>), and others.</p></div></div><div id="fa.Genetically_Related_Allelic_Disorders"><h2 id="_fa_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>Hereditary breast and ovarian cancer is associated with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>BRCA2</i>.</p><p>Heterozygous pathogenic variants in <i>BRIP1</i> and <i>PALB2</i> have been implicated in breast cancer and ovarian cancer predisposition [<a class="bk_pop" href="#fa.REF.seal.2006.1239">Seal et al 2006</a>, <a class="bk_pop" href="#fa.REF.rahman.2007.165">Rahman et al 2007</a>, <a class="bk_pop" href="#fa.REF.rafnar.2011.1104">Rafnar et al 2011</a>].</p><p>Heterozygous pathogenic variants in <i>PALB2</i> have been implicated in pancreatic cancer predisposition [<a class="bk_pop" href="#fa.REF.jones.2009.217">Jones et al 2009</a>].</p><p>Biallelic pathogenic variants in <i>ERCC4</i> are associated with <a href="/books/n/gene/xp/">xeroderma pigmentosum</a>, <a href="/books/n/gene/cockayne/">Cockayne syndrome</a>, and XFE progeroid syndrome.</p></div><div id="fa.Differential_Diagnosis"><h2 id="_fa_Differential_Diagnosis_">Differential Diagnosis</h2><p>Cells derived from individuals with other <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage syndromes, such as <a href="/books/n/gene/bloom/">Bloom syndrome</a> or <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a>, may also exhibit high rates of spontaneous chromosome breakage; however, only FA cells exhibit increased chromosome breakage in response to diepoxybutane (DEB).</p><p><a href="/books/n/gene/nijmegen/">Nijmegen breakage syndrome</a> (NBS), characterized by short stature, progressive microcephaly with loss of cognitive skills, premature ovarian failure in females, recurrent sinopulmonary infections, and an increased risk for cancer (particularly lymphoma), may also manifest increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage with mitomycin C (MMC) [<a class="bk_pop" href="#fa.REF.chrzanowska.2012.13">Chrzanowska et al 2012</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>. NBS may be distinguished from FA by <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, which identifies pathogenic variants in almost 100% of individuals with NBS.</p><p>Seckel syndrome (OMIM <a href="http://omim.org/phenotypicSeries/PS210600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS210600</a>), characterized by growth retardation, microcephaly with intellectual disability, and a characteristic "bird-headed" facial appearance, may also show increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage with DNA cross-linking agents (MMC, DEB) [<a class="bk_pop" href="#fa.REF.andreassen.2004.1958">Andreassen et al 2004</a>]. Some individuals with Seckel syndrome also develop pancytopenia and/or AML. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>. Biallelic pathogenic variants in <i>ATR</i>, <i>NIN</i>, <i>ATRIP</i>, <i>RBBP8</i>, <i>CEP152</i>, <i>CENPJ</i>, and <i>CEP63</i> are causative.</p><p>Other disorders including <a href="/books/n/gene/nf1/">neurofibromatosis 1</a> (which could be considered because of caf&#x000e9; au lait macules), <a href="/books/n/gene/tar/">TAR syndrome</a> (thrombocytopenia with absent radii), and VACTERL association (radial ray defects) (OMIM <a href="http://omim.org/entry/192350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">192350</a>) can be distinguished from FA by testing for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage with DEB and MMC.</p></div><div id="fa.Management"><h2 id="_fa_Management_">Management</h2><div id="fa.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and management requirements in an individual diagnosed with Fanconi anemia (FA), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div class="half_rhythm">Evaluation by a hematologist, to include complete blood count, fetal hemoglobin, full blood typing, blood chemistries (assessing liver, kidney, and iron status), and bone marrow aspirate for cell morphology, <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> and cytogenetics, as well as biopsy for cellularity</div><div class="half_rhythm">Note: The bone marrow of individuals with FA can exhibit signs of dysplasia, such as nuclear/cytoplasmic dys-synchrony, hypo-lobulated megakaryocytes, and bi-nucleated erythroid cells. These features must be distinguished from true forms of MDS by a hematopathologist experienced in the evaluation of MDS in individuals with FA.</div></li><li class="half_rhythm"><div class="half_rhythm">HLA typing of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, sibs, and parents for consideration of hematopoietic stem cell transplantation</div></li><li class="half_rhythm"><div class="half_rhythm">Examination by an ophthalmologist</div></li><li class="half_rhythm"><div class="half_rhythm">Ultrasound examination of the kidneys and urinary tract</div></li><li class="half_rhythm"><div class="half_rhythm">Formal hearing evaluation</div></li><li class="half_rhythm"><div class="half_rhythm">Echocardiogram</div></li><li class="half_rhythm"><div class="half_rhythm">Referral to an endocrinologist</div></li><li class="half_rhythm"><div class="half_rhythm">Developmental assessment (particularly important for toddlers and school-age children)</div></li><li class="half_rhythm"><div class="half_rhythm">Referrals as indicated to an otolaryngologist, hand surgeon, gastroenterologist, gynecologist, and urologist</div></li><li class="half_rhythm"><div class="half_rhythm">Evaluation by a clinical geneticist and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a></div></li></ul></div><div id="fa.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Recommendations for treatment were agreed upon at a 2014 consensus conference (<a href="http://fanconi.org/images/uploads/other/FA_Guidelines_4th_Edition_Revised_Names_in_Appendix.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p><b>Androgens</b> improve (at least transiently) the red cell and platelet counts in approximately 50% of individuals. Androgen therapy can be considered when the hemoglobin drops below 8 g/dL or the platelet count falls below 30,000/mm<sup>3</sup> ("severe" &#x02013; see <a class="figpopup" href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object" rid-figpopup="figfaTseverityofbonemarrowfailurein" rid-ob="figobfaTseverityofbonemarrowfailurein">Table 2</a>). Although only 10%-20% of individuals receiving continuous low-dose androgen therapy are long-term responders, this option can be particularly useful for individuals who do not have access to or are not ready for hematopoietic stem cell transplant (HSCT), or to individuals for whom of a suitable donor is not available.</p><ul><li class="half_rhythm"><div>Oxymetholone, given orally at a starting dose of 2 mg/kg/day, may be increased up to 5 mg/kg/day.</div></li><li class="half_rhythm"><div>Doses may be slowly tapered to the minimal effective dose with careful monitoring of the blood counts.</div></li><li class="half_rhythm"><div>Other synthetic androgens used in FA include stanazolol in Asia, and oxandrolone and danazol in North America.</div></li></ul><p>Side effects of androgen administration include virilization and liver toxicity such as elevated liver enzymes, cholestasis, peliosis hepatis (vascular lesion with multiple blood-filled cysts), and hepatic tumors. Individuals taking androgens should be monitored for liver tumors and undergo regular liver function tests (LFT) for abnormalities. Blood tests for LFTs should be performed every three to six months; liver ultrasound should be performed every six to 12 months. If no response is seen after three to four months, androgens should be discontinued [<a class="bk_pop" href="#fa.REF.scheckenbach.2012.128">Scheckenbach et al 2012</a>, <a class="bk_pop" href="#fa.REF.rose.2014.11">Rose et al 2014</a>].</p><p><b>Granulocyte colony-stimulating factor</b> (G-CSF) improves the neutrophil count in some individuals. G-CSF dose should be titrated to the lowest possible dose and frequency to keep ANC above 1,000/mm<sup>3</sup>. Note: (1) A bone marrow aspirate and biopsy should be performed prior to the initiation of G-CSF and monitored every six months throughout treatment, given the theoretic risk of stimulating the growth of a leukemic clone. (2) G-CSF should be administered in consultation with an FA expert.</p><p><b>Hematopoietic stem cell transplantation</b> (HSCT) is the only curative therapy for the hematologic manifestations, including aplastic anemia, myelodysplastic syndrome, and acute leukemia. Ideally, HSCT is performed prior to onset of MDS/AML and before multiple transfusions [<a class="bk_pop" href="#fa.REF.macmillan.2010.14">MacMillan &#x00026; Wagner 2010</a>, <a class="bk_pop" href="#fa.REF.mehta.2010.180">Mehta et al 2010</a>]. Individuals with FA are sensitive to chemotherapy and radiation, need special transplant regimens, and should be cared for and transplanted at centers with the most experience in HSCT in FA.</p><p>A multi-institutional study reported a one-year probability of overall survival of 80% in 45 individuals with FA transplanted for marrow failure and/or MDS, using alternative donors (including mismatched related and unrelated donors) and chemotherapy-only preparative regimen. Survival for individuals younger than age ten years transplanted for marrow failure was even better, at 91.3% (&#x000b1;5.9%) [<a class="bk_pop" href="#fa.REF.mehta.2017.2308">Mehta et al 2017</a>].</p><p><b>Fludarabine</b> reduced the incidence of graft failure and allowed for removal of radiation from the preparative regimens in a matched sib donor setting [<a class="bk_pop" href="#fa.REF.macmillan.2015.3798">MacMillan et al 2015</a>].</p><p><b>MDS/AML</b> treatment remains challenging. Options include chemotherapy, HSCT with or without prior induction chemotherapy, and investigational trials. Chemotherapy should be undertaken in coordination with centers experienced with FA, as it can cause severe, prolonged, or irreversible myelosuppression. Plans for HSCT should be in place prior to starting chemotherapy. Published reports of chemotherapy regimens for AML in individuals with FA are sparse and limited by the unclear benefit to the overall outcome due to the lack of longitudinal follow up [<a class="bk_pop" href="#fa.REF.mehta.2007.668">Mehta et al 2007</a>, <a class="bk_pop" href="#fa.REF.talbot.2014.e199">Talbot et al 2014</a>, <a class="bk_pop" href="#fa.REF.beier.2015.463">Beier et al 2015</a>].</p><p><b>Solid tumors.</b> Prompt, aggressive workup for any symptoms suggestive of a malignancy is indicated. Early detection and surgical removal remains the mainstay of therapy. Treatment is challenging secondary to the increased toxicity associated with chemotherapy and radiation in FA. Data is limited on use of chemotherapy at standard doses or reduced doses and schedules in individuals with FA, and there are reports of severe or fatal toxicities and poor treatment outcomes [<a class="bk_pop" href="#fa.REF.masserot.2008.3315">Masserot et al 2008</a>, <a class="bk_pop" href="#fa.REF.hosoya.2010.805">Hosoya et al 2010</a>, <a class="bk_pop" href="#fa.REF.tan.2011.e591">Tan et al 2011</a>, <a class="bk_pop" href="#fa.REF.spanier.2012.510">Spanier et al 2012</a>]. Individuals diagnosed with a genital tract cancer should be referred to a gynecologic oncologist immediately, and care should be coordinated with FA experts.</p></div><div id="fa.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Human papilloma virus (HPV) vaccination should be initiated at age nine years in order to reduce the risk of gynecologic cancer in females, and possibly reduce the risk of oral cancer in all individuals.</p></div><div id="fa.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>Individuals with FA treated with HSCT who developed graft vs host disease (GVHD) had a 28% incidence of head and neck cancers in the ten years following treatment (vs 0% in those without GVHD); this finding points to the importance of minimizing the risk of GVHD [<a class="bk_pop" href="#fa.REF.guardiola.2004.73">Guardiola et al 2004</a>]. Increased risk for GVHD observed in earlier studies was reduced significantly by T-cell depletion of the donor graft [<a class="bk_pop" href="#fa.REF.chaudhury.2008.644">Chaudhury et al 2008</a>, <a class="bk_pop" href="#fa.REF.macmillan.2015.3798">MacMillan et al 2015</a>].</p><p>Individuals successfully treated with HSCT are at increased risk for solid tumors, in addition to the baseline increased risk [<a class="bk_pop" href="#fa.REF.rosenberg.2005.67">Rosenberg et al 2005</a>]. Due to the known contribution of radiation to the long-term complication of secondary solid tumors most recent efforts have focused on using a conditioning regimen without radiation even in an unrelated donor setting. German, Brazilian, and US groups now report excellent outcomes with alternative donors with a "chemotherapy-only" preparative regimen in single-center studies. The study from Germany showed 88% survival and normal hematopoiesis at a median follow up of 30 months [<a class="bk_pop" href="#fa.REF.bonfim.2015.s94a">Bonfim et al 2015</a>, <a class="bk_pop" href="#fa.REF.chao.2015.1311">Chao et al 2015</a>]. A prospective multi-institutional US study also showed similar excellent outcomes. One-year probabilities of overall and disease-free survival for the entire cohort, including patients with myeloid malignancy and those receiving mismatched related/haploidentical grafts, were 80% and 77.7% respectively at a median follow-up of 41 months. All young children (age &#x0003c;10 years) undergoing HSCT for marrow failure using low-dose busulfan-containing regimen survived [<a class="bk_pop" href="#fa.REF.mehta.2017.2308">Mehta et al 2017</a>].</p></div><div id="fa.Surveillance"><h3>Surveillance</h3><p>See 2014 consensus guidelines [<a class="bk_pop" href="#fa.REF.frohnmayer.2014">Frohnmayer et al 2014</a>] (<a href="http://fanconi.org/images/uploads/other/FA_Guidelines_4th_Edition_Revised_Names_in_Appendix.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><ul><li class="half_rhythm"><div>Annual evaluation with a multidisciplinary team including an endocrinologist</div></li><li class="half_rhythm"><div>Regular blood counts, every three to four months while stable and more often as needed</div></li><li class="half_rhythm"><div>Bone marrow aspirate/biopsy at least annually to evaluate morphology, cellularity (from the biopsy), <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a>, and cytogenetics (the latter two for emergence of a malignant clone). Individuals on GCSF need to have a bone marrow aspirate/biopsy every six months, if possible.</div></li><li class="half_rhythm"><div>In individuals who develop Sweet syndrome (neutrophilic skin infiltration), prompt investigation for hematologic disease progression including bone marrow evaluation</div></li></ul><p>Notes: (1) Progressively changing blood counts without a potential cause (e.g., acute infection or suppression from medication) require immediate evaluation with a complete blood count and bone marrow examination with <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> and cytogenetics. (2) It is important to recognize that rising blood counts can be due to either the development of MDS/AML or, rarely, reversion of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> mutation in a stem cell, which repopulates the marrow with normal cells (somatic stem cell <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>). These individuals may require immediate HSCT (for MDS/AML) or continued close monitoring with complete blood counts at least every one to two months and a bone marrow examination with cytogenetics every six months.</p><p><b>Individuals receiving androgen therapy</b></p><ul><li class="half_rhythm"><div>Liver function tests every three to six months</div></li><li class="half_rhythm"><div>Liver ultrasound examination every six to 12 months for androgen-related changes, including tumors</div></li></ul><p><b>Cancer surveillance</b></p><ul><li class="half_rhythm"><div>Annual gynecologic assessment for genital lesions beginning at age 13. Thorough vulvo-vaginal examinations and Pap smear can begin when women become sexually active or by age 18 years, whichever is earlier. Suspicious genital tract lesions should be biopsied.</div></li><li class="half_rhythm"><div>Examination every six months for oral, head, and neck cancers beginning by age nine to ten years. Screening should be performed by a dentist, oral surgeon, or ENT familiar with FA. Nasolaryngoscopy starting at age ten years, or within the first year after HSCT. Individuals with difficulty or pain with swallowing should be evaluated for esophageal cancer.</div></li><li class="half_rhythm"><div>For individuals with a history of premalignant or malignant lesions: surveillance examinations every two to three months</div></li><li class="half_rhythm"><div>For individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BRCA2</i>: screening for neuroblastomas, brain tumors, and kidney tumors every six months (see also Autosomal Recessive FA, <a href="#fa.Risk_to_Family_Members">Risk to Family Members</a>)</div></li></ul></div><div id="fa.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Blood transfusions.</b> Blood products should be cytomegalovirus (CMV)-safe and irradiated. To reduce the chances of sensitization, family members must not act as blood donors. Once an individual requires transfusions, he/she should be referred for transplantation.</p><p><b>Toxic agents</b> to avoid include smoking, second-hand smoke, and alcohol, which have been implicated in tumorigenesis.</p><p><b>Unsafe sex practices</b> increase the risk for HPV-associated malignancy.</p><p><b>Radiographic studies</b> for the purpose of surveillance should be minimized in the absence of clinical indications. However, baseline skeletal surveys may be considered, in order to document bony anomalies that may lead to problems with age, such as anomalies of the wrist, hip, and vertebrae.</p></div><div id="fa.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate all sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from appropriate monitoring for physical abnormalities, bone marrow failure, and related cancers.</p><ul><li class="half_rhythm"><div>DEB/MMC testing can be used to clarify the disease status of at-risk sibs.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk sibs.</div></li></ul><p>See <a href="#fa.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="fa.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is possible in females with FA, whether or not they have undergone hematopoietic stem cell transplantation [<a class="bk_pop" href="#fa.REF.dalle.2004.1099">Dalle et al 2004</a>, <a class="bk_pop" href="#fa.REF.nabhan.2010.1783">Nabhan et al 2010</a>].</p><p>Pregnancy needs to be managed by a high-risk maternal fetal obstetrician along with a hematologist.</p></div><div id="fa.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Previous clinical trials failed to accomplish permanent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> correction of stem cells; current work is focusing on development of novel vector and delivery strategies [<a class="bk_pop" href="#fa.REF.tolar.2011.1193">Tolar et al 2011</a>]. The first FA lentiviral <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> trial led by the University of Washington/Fred Hutchinson Cancer Research Center is now open [<a class="bk_pop" href="#fa.REF.becker.2010.1244">Becker et al 2010</a>]. Dr Juan Bueren has an open trial of a hematopoietic stem cell mobilization in Madrid, Spain and plans to have their <i>FANCA</i> gene therapy trial opened soon.</p><p>A Phase I study of the antioxidant quercetin in children with Fanconi anemia is currently underway at Cincinnati Children's Hospital Medical Center.</p><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="fa.Genetic_Counseling"><h2 id="_fa_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="fa.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Fanconi anemia (FA) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (<i>RAD51</i>-related FA), or an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner (<i>FANCB</i>-related FA).</p></div><div id="fa.Autosomal_Recessive_FA"><h3>Autosomal Recessive FA</h3><div id="fa.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a child with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA are obligate heterozygotes (i.e., carriers of one FA-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are not at risk for FA. However, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mutation of a subset of FA-related genes (e.g., <i>BRCA2</i>, <i>PALB2</i>, and <i>BRIP1</i>) is associated with an increased risk for breast and other cancers [<a class="bk_pop" href="#fa.REF.seal.2006.1239">Seal et al 2006</a>, <a class="bk_pop" href="#fa.REF.berwick.2007.9591">Berwick et al 2007</a>, <a class="bk_pop" href="#fa.REF.rahman.2007.165">Rahman et al 2007</a>] (see <a href="/books/n/gene/brca1/">Hereditary Breast and Ovarian Cancer</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are not at risk for FA. However, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mutation of a subset of FA-related genes (e.g., <i>BRCA2</i>, <i>PALB2</i>, and <i>BRIP1</i>) is associated with an increased risk for breast and other cancers [<a class="bk_pop" href="#fa.REF.seal.2006.1239">Seal et al 2006</a>, <a class="bk_pop" href="#fa.REF.berwick.2007.9591">Berwick et al 2007</a>, <a class="bk_pop" href="#fa.REF.rahman.2007.165">Rahman et al 2007</a>] (see <a href="/books/n/gene/brca1/">Hereditary Breast and Ovarian Cancer</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FA are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an FA-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an FA-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div><div id="fa.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the FA-related pathogenic variants in the family.</p><p>Carriers of FA cannot be detected by the DEB/MMC test.</p></div></div><div id="fa.Autosomal_Dominant_FA__Risk_to_Family"><h3>Autosomal Dominant FA &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, reported probands with <i>RAD51</i>-related FA have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>RAD51</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>RAD51</i>-related FA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, suggesting a low risk to sibs. However, because of the theoretic possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent, the risk is presumed to be greater than in the general population.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <i>RAD51</i>-related FA is presumed to have a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. However, only one individual with <i>RAD51</i>-related FA has reached adulthood and no offspring have been reported.</p><p><b>Other family members.</b> Given that all probands with <i>RAD51</i>-related FA reported to date have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>RAD51</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to other family members is presumed to be low.</p></div><div id="fa.XLinked_FA"><h3>X-Linked FA</h3><div id="fa.Risk_to_Family_Members_1"><h4>Risk to Family Members</h4><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The father of a male with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> FA will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div class="half_rhythm">In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</div><div class="half_rhythm">Note: If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> son and if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit the pathogenic variant will be carriers and will usually not be affected.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Affected males transmit the <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters (who will be carriers and will usually not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>) and none of their sons.</div></li><li class="half_rhythm"><div>To date, no male with FA-B has been old enough to have children; they may also be infertile, as are many males with FA.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The proband's maternal aunts may be at risk of being heterozygotes (carriers) for the <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the aunt's offspring, depending on their gender, may be at risk of being carriers or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>Note: Molecular genetic testing may be able to identify the family member in whom a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose &#x02013; information that could help determine genetic risk status of the extended family.</p></div><div id="fa.Heterozygote_Carrier_Detection"><h4>Heterozygote (Carrier) Detection</h4><p>Carrier testing for at-risk female relatives requires prior identification of the <i>FANCB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p>Carriers of FA cannot be detected by the DEB/MMC test.</p></div></div><div id="fa.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#fa.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="fa.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the FA-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for FA are possible. Preimplantation genetic diagnosis has successfully identified at-risk embryos as unaffected with FA and HLA-matched to affected sibs [<a class="bk_pop" href="#fa.REF.kahraman.2014.340">Kahraman et al 2014</a>].</p><p><b>Chromosome breakage.</b> Prenatal testing is also possible for pregnancies at increased risk for FA by performing <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> testing in the presence of DEB/MMC to evaluate for increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage in fetal cells obtained by chorionic villus sampling (CVS) or amniocentesis; however, if the pathogenic variants are known in the family, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the method of choice for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>.</p><p><b>Fetal ultrasound evaluation.</b> Ultrasound examination can be used to evaluate for fetal anomalies consistent with FA. However, ultrasound examination is not a diagnostic test for FA. Many <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies characteristic of FA may not be detectable by ultrasound examination, and those that can be seen may be associated with diagnoses other than FA.</p></div></div><div id="fa.Resources"><h2 id="_fa_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Fanconi Anemia Cell Repository</b></div><div>Department of Medical and Molecular Genetics</div><div>3181 Southwest Sam Jackson Park Road L103</div><div>Oregon Health &#x00026; Science University</div><div>Portland OR 97201</div><div><b>Phone:</b> 503-494-6888</div></li><li class="half_rhythm"><div><b>Fanconi Anemia Research Fund, Inc. (FARF)</b></div><div>1801 Williamette Street</div><div>Suite 200</div><div>Eugene OR 97401</div><div><b>Phone:</b> 888-326-2664 (Toll-free Family Support Line); 541-687-4658</div><div><b>Fax:</b> 541-687-0548</div><div><b>Email:</b> info@fanconi.org</div><div><a href="http://www.fanconi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fanconi.org</a></div></li><li class="half_rhythm"><div><b>International Fanconi Anemia Registry (IFAR)</b></div><div>The Rockefeller University</div><div>1230 York Avenue</div><div>New York NY 10065</div><div><b>Phone:</b> 212-327-8862</div><div><b>Fax:</b> 212-327-8262</div><div><b>Email:</b> auerbac@rockefeller.edu</div><div><a href="http://lab.rockefeller.edu/smogorzewska/ifar/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Fanconi Anemia Registry (IFAR)</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute Inherited Bone Marrow Failure Syndromes (IBMFS) Cohort Registry</b></div><div><b>Phone:</b> 800-518-8474</div><div><b>Email:</b> NCI.IBMFS@westat.com</div><div><a href="https://www.marrowfailure.cancer.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.marrowfailure.cancer.gov</a></div></li><li class="half_rhythm"><div><b>Prospective Registry of MultiPlex Testing (PROMPT)</b></div><div><i>PROMPT is an online research registry for patients and families who have undergone multiplex genetic testing and were found to have a genetic variation which may be linked to an increased risk of having cancer.</i></div><div><a href="https://connect.patientcrossroads.org/?org=prompt" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PROMPT</a></div></li></ul></div><div id="fa.Molecular_Genetics"><h2 id="_fa_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="fa.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Fanconi Anemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/675" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRCA2</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=675" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">13q13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51587" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast cancer type 2 susceptibility protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2 homepage - LOVD</a><br /><a href="http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Database of BRCA1 and BRCA2 sequence variants that have been clinically reclassified using a quantitative integrated evaluation</a><br /><a href="https://research.nhgri.nih.gov/bic/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Breast Cancer Information Core (BRCA2)</a><br /><a href="http://www.rockefeller.edu/fanconi/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCD1 - BRCA2)</a><br /><a href="https://lovd.nl/BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2 @ ZAC-GGM</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRCA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRCA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRCA2</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/83990" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRIP1</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=83990" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q23<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BX63" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group J protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/BRIP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRIP1 @ LOVD</a><br /><a href="https://www.lovd.nl/FANCJ" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCJ - BRIP1)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRIP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRIP1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRIP1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRIP1</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2072" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ERCC4</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2072" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair endonuclease XPF</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ERCC4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4 database</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ERCC4</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2175" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCA</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2175" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O15360" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group A protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anemia Mutation Database (FANCA)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCA" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCA</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCA[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCA</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2187" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCB</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2187" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp22<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8NB91" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group B protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/FANCB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCB @ LOVD</a><br /><a href="https://www.lovd.nl/FANCB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCB)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCB</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCB</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2176" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCC</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2176" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q22<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q00597" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group C protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/FANCC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anemia Mutation Database (FANCC)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCC</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCC[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCC</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2177" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCD2</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2177" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p25<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BXW9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group D2 protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCD2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCD2)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCD2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCD2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCD2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCD2</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2178" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCE</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2178" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p21<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9HB96" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group E protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCE)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCE" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCE</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCE[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCE</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2188" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCF</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2188" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p14<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NPI8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group F protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCF)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCF</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCF[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCF</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2189" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCG</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2189" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O15287" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group G protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCG)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCG</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCG[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCG</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/55215" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCI</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=55215" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q26<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NVI1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group I protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCI" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anemia Mutation Database (FANCI)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCI" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCI</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCI[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCI</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/55120" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCL</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=55120" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p16<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NW38" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">E3 ubiquitin-protein ligase FANCL</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.lovd.nl/FANCL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCL)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCL</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCL[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCL</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/57697" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FANCM</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=57697" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8IYD8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi anemia group M protein</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/FANCM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fanconi Anaemia Mutation Database (FANCM)</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCM</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCM[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FANCM</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/10459" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MAD2L2</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=10459" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p36<wbr style="display:inline-block"></wbr>​.22</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UI95" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mitotic spindle assembly checkpoint protein MAD2B</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAD2L2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAD2L2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAD2L2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAD2L2</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/79728" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PALB2</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=79728" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p12<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q86YC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Partner and localizer of BRCA2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/PALB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PALB2 database</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PALB2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PALB2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PALB2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PALB2</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5888" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RAD51</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5888" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q15<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q06609" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein RAD51 homolog 1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/RAD51" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51 database</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAD51" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAD51[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5889" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RAD51C</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">17q22</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O43502" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein RAD51 homolog 3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/RAD51C" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51C @ LOVD</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAD51C" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51C</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAD51C[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAD51C</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/55159" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RFWD3</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=55159" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16q23<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q6PCD5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">E3 ubiquitin-protein ligase RFWD3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RFWD3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RFWD3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RFWD3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RFWD3</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/84464" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLX4</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=84464" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8IY92" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Structure-specific endonuclease subunit SLX4</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/SLX4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLX4 @ LOVD</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLX4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLX4</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLX4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLX4</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/29089" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>UBE2T</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=29089" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q32<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NPD8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ubiquitin-conjugating enzyme E2 T</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UBE2T" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UBE2T</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UBE2T[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UBE2T</a></td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7516" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>XRCC2</i></a></td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7516" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q36<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O43543" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA repair protein XRCC2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/XRCC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XRCC2 @ LOVD</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XRCC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XRCC2</a></td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XRCC2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">XRCC2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="fa.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="fa.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Fanconi Anemia (<a href="/omim/133520,179617,227645,227646,227650,300514,300515,600185,600375,600901,602774,602956,603467,604094,605724,605882,607139,608111,609053,609054,609644,610355,610538,610832,611360,613278,613390,613897,613899,613951,613976,613984,614082,614083,614087,614151,615272,616435,617243,617244,617247,617784" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/133520" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">133520</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 4; ERCC4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/179617" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">179617</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAD51 RECOMBINASE; RAD51</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/227645" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">227645</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/227646" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">227646</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/227650" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">227650</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300514" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300514</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300515" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300515</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCB GENE; FANCB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600185" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600185</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA2 GENE; BRCA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600375" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600375</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 2; XRCC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600901" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600901</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602774" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602774</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAD51 PARALOG C; RAD51C</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602956" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602956</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCG GENE; FANCG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603467" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603467</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604094" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604094</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOTIC ARREST-DEFICIENT 2 LIKE 2; MAD2L2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605724" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605724</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605882" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605882</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA1-INTERACTING PROTEIN 1; BRIP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607139" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607139</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCA GENE; FANCA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608111" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608111</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCL GENE; FANCL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609053" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609053</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609054" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609054</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609644" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609644</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCM GENE; FANCM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610355" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610355</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARTNER AND LOCALIZER OF BRCA2; PALB2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610538" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610538</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UBIQUITIN-CONJUGATING ENZYME E2T; UBE2T</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610832" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610832</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/611360" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611360</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCI GENE; FANCI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613278" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613278</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SLX4 STRUCTURE-SPECIFIC ENDONUELEASE SUBUNIT; SLX4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613390" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613390</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613897" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613897</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCF GENE; FANCF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613899" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613899</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCC GENE; FANCC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613951" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613951</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613976" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613976</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCE GENE; FANCE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613984" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613984</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCD2 GENE; FANCD2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614082" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614082</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614083" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614083</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614087" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614087</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP M; FANCM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614151" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614151</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 3; RFWD3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615272" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615272</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/616435" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616435</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/617243" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">617243</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP V; FANCV</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/617244" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">617244</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP R; FANCR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/617247" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">617247</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP U; FANCU</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/617784" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">617784</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP W; FANCW</td></tr></tbody></table></div></div><p>See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a> for <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein names.</p><p>For a table of Fanconi anemia-associated proteins and their function, click <a href="http://www.sciencedirect.com/science/article/pii/S0092867414016377" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> and download pdf [<a class="bk_pop" href="#fa.REF.wang.2015.354">Wang &#x00026; Smogorzewska 2015</a>].</p><div id="fa.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>At least twenty genes that are involved in Fanconi anemia (FA) and also account for each of the phenotypic complementation groups have been identified. The proteins encoded by the FA-related genes are considered to work together in a common pathway/network called "the FA pathway" or "the FA-BRCA pathway/network," which regulates cellular resistance to DNA cross-linking agents [<a class="bk_pop" href="#fa.REF.taniguchi.2006.4223">Taniguchi &#x00026; D'Andrea 2006</a>, <a class="bk_pop" href="#fa.REF.dandrea.2010.1909">D'Andrea 2010</a>, <a class="bk_pop" href="#fa.REF.deans.2011.467">Deans &#x00026; West 2011</a>, <a class="bk_pop" href="#fa.REF.kee.2012.3799">Kee &#x00026; D'Andrea 2012</a>]. Disruption of this pathway leads to the common cellular and clinical abnormalities observed in FA [<a class="bk_pop" href="#fa.REF.dandrea.2010.1909">D'Andrea 2010</a>, <a class="bk_pop" href="#fa.REF.nakanishi.2011.500">Nakanishi et al 2011</a>, <a class="bk_pop" href="#fa.REF.williams.2011b.4395">Williams et al 2011b</a>, <a class="bk_pop" href="#fa.REF.crossan.2012.326">Crossan &#x00026; Patel 2012</a>, <a class="bk_pop" href="#fa.REF.kim.2012.1393">Kim &#x00026; D'Andrea 2012</a>].</p><p>Eight of the FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM), along with proteins FAAP24 [<a class="bk_pop" href="#fa.REF.ciccia.2007.331">Ciccia et al 2007</a>] and FAAP100 [<a class="bk_pop" href="#fa.REF.ling.2007.2104">Ling et al 2007</a>] are assembled in a nuclear complex (FA core complex). This complex is a multisubunit ubiquitin ligase complex; monoubiquitination of two FA proteins (FANCD2 and FANCI) depends on the FA core complex [<a class="bk_pop" href="#fa.REF.garciahiguera.2001.249">Garcia-Higuera et al 2001</a>, <a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. In response to DNA damage or in S phase of the cell cycle, this FA core complex activates the monoubiquitination of the FANCD2 and FANCI proteins. Monoubiquitinated FANCD2 and monoubiquitinated FANCI are translocated to nuclear foci containing the proteins BRCA1, BRCA2, PALB2, and RAD51. FANCI shares sequence similarity with FANCD2; together they form a protein complex (ID complex) [<a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. Monoubiquitination of FANCD2 and FANCI is interdependent [<a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. A nuclease, FAN1, has been shown to bind to monoubiquitinated FANCD2, which directs its enzymatic activity [<a class="bk_pop" href="#fa.REF.huang.2010.926">Huang &#x00026; D'Andrea 2010</a>]. A cell-free system has been used to recapitulate cross-link repair in vitro [<a class="bk_pop" href="#fa.REF.knipscheer.2009.1698">Knipscheer et al 2009</a>].</p><p>One of the components of the FA core complex, FANCL, has a PHD (plant homeodomain) finger (a variant RING finger) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> with ubiquitin ligase activity [<a class="bk_pop" href="#fa.REF.meetei.2003a.165">Meetei et al 2003a</a>]. FANCL associates through its PHD/RING finger domain with UBE2T, a ubiquitin conjugating enzyme (E2), which is also required for FANCD2 monoubiquitination [<a class="bk_pop" href="#fa.REF.machida.2006.589">Machida et al 2006</a>]. Recombinant FANCL, the E2 UBE2T, FANCD2, FANCI, and FANCE recapitulate the monoubiquitination reaction in vitro [<a class="bk_pop" href="#fa.REF.alpi.2008.767">Alpi et al 2008</a>].</p><p>Another component of the FA core complex, FANCM, is homologous to the archaeal DNA helicase/nuclease known as HEF. FANCM has DNA helicase motifs and a degenerate nuclease motif and exhibits DNA-stimulated ATPase activity and DNA translocase activity [<a class="bk_pop" href="#fa.REF.meetei.2005.958">Meetei et al 2005</a>]. A FANCM-interacting protein, FAAP24, preferentially binds to single-stranded DNA and branched DNA structures [<a class="bk_pop" href="#fa.REF.ciccia.2007.331">Ciccia et al 2007</a>]. Therefore, it has been speculated that FANCM DNA translocase activity could play an important role in displacing the FA core complex along the DNA, allowing DNA damage recognition, or that FAAP24 may play a role in targeting the FA core complex to abnormal, branched DNA structures. This complex is thought to be responsible for a replication-associated checkpoint response involving RPA [<a class="bk_pop" href="#fa.REF.huang.2010.259">Huang et al 2010</a>] and the BLM helicase [<a class="bk_pop" href="#fa.REF.deans.2009.943">Deans &#x00026; West 2009</a>]. As is true for multiple FA proteins, the complex appears to be regulated through ATR [<a class="bk_pop" href="#fa.REF.collis.2008.313">Collis et al 2008</a>].</p><p>Furthermore, the FA core complex forms a larger complex with BLM, RPA, and topoisomerase III&#x003b1;, called BRAFT (<i>B</i>LM, <i>R</i>P<i>A</i>, <i>F</i>A, and <i>t</i>opoisomerase III&#x003b1;) [<a class="bk_pop" href="#fa.REF.meetei.2003b.3417">Meetei et al 2003b</a>] in a further link to <a href="/books/n/gene/bloom/">Bloom syndrome</a>. FANCM is found in both separable complexes: the FA core complex as well as the BLM complex [<a class="bk_pop" href="#fa.REF.deans.2009.943">Deans &#x00026; West 2009</a>].</p><p>A DNA damage-activated signaling kinase, ATR, a single-strand DNA-binding protein complex, RPA, and an ATR-associated protein, HCLK2, are required for DNA damage-inducible monoubiquitnation and foci formation of FANCD2 [<a class="bk_pop" href="#fa.REF.andreassen.2004.1958">Andreassen et al 2004</a>, <a class="bk_pop" href="#fa.REF.collis.2007.391">Collis et al 2007</a>]. BRCA1 [<a class="bk_pop" href="#fa.REF.garciahiguera.2001.249">Garcia-Higuera et al 2001</a>, <a class="bk_pop" href="#fa.REF.vandenberg.2003.247">Vandenberg et al 2003</a>] and histone H2AX [<a class="bk_pop" href="#fa.REF.bogliolo.2007.1340">Bogliolo et al 2007</a>] are required for DNA damage-inducible foci formation of FANCD2, but not for monoubiquitination of FANCD2. These factors are considered to be upstream positive regulators of the FA pathway. ATR has been shown to directly phosphorylate FANCA and indirectly phosphorylate FANCD2 through CHK1 [<a class="bk_pop" href="#fa.REF.zhi.2009.8775">Zhi et al 2009</a>]. As described, ATR is also necessary for assembly of FANCM and recruitment of RPA at the ICL-induced checkpoint [<a class="bk_pop" href="#fa.REF.collis.2008.313">Collis et al 2008</a>].</p><p><i>BRCA2</i> (previously <i>FANCD1</i>) is a tumor suppressor that confers breast cancer susceptibility [<a class="bk_pop" href="#fa.REF.howlett.2002.606">Howlett et al 2002</a>] and has a distinct clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#fa.REF.wagner.2004.3226">Wagner et al 2004</a>, <a class="bk_pop" href="#fa.REF.alter.2007.1">Alter et al 2007</a>, <a class="bk_pop" href="#fa.REF.myers.2012.462">Myers et al 2012</a>]. BRCA2 protein stability and localization is regulated by PALB2 (partner and localizer of BRCA2) [<a class="bk_pop" href="#fa.REF.xia.2006.719">Xia et al 2006</a>] encoded by <i>PALB2</i> (previously <i>FANCN</i>), another breast cancer susceptibility <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#fa.REF.rahman.2007.165">Rahman et al 2007</a>]. Another breast cancer susceptibility gene [<a class="bk_pop" href="#fa.REF.seal.2006.1239">Seal et al 2006</a>], <i>BRIP1</i> (previously <i>BACH1</i> or <i>FANCJ</i>) [<a class="bk_pop" href="#fa.REF.cantor.2001.149">Cantor et al 2001</a>], is also assoicated with FA [<a class="bk_pop" href="#fa.REF.levitus.2005.934">Levitus et al 2005</a>, <a class="bk_pop" href="#fa.REF.levran.2005.931">Levran et al 2005</a>, <a class="bk_pop" href="#fa.REF.litman.2005.255">Litman et al 2005</a>]. <i>BRCA2, PALB2</i>, and <i>BRIP1</i> are not required for FANCD2 protein monoubiquitination or FANCD2 nuclear foci formation, but are still required for cellular resistance to MMC or DEB. BRCA2 has been found to act in multiple subcomplexes of FA proteins, including FANCG and FANCD2 [<a class="bk_pop" href="#fa.REF.wilson.2010.12">Wilson et al 2010</a>], suggesting that the notion of acting downstream of FANCD2 monoubiquitination may be too simplistic. Phosphorylation of FANCD2 by CHK1 has been shown to be necessary for interaction with BRCA2 [<a class="bk_pop" href="#fa.REF.zhi.2009.8775">Zhi et al 2009</a>]. BRIP1 and FANCD2 have also been shown to be functionally linked in foci formation [<a class="bk_pop" href="#fa.REF.zhang.2010.637">Zhang et al 2010</a>].</p><p>USP1 is a deubiquitinating enzyme that removes ubiquitin from monoubiquitinated FANCD2, and negatively regulates the FA pathway along with its coactivator UAF1 [<a class="bk_pop" href="#fa.REF.nijman.2005.331">Nijman et al 2005</a>, <a class="bk_pop" href="#fa.REF.cohn.2007.786">Cohn et al 2007</a>]. USP1 also removes ubiquitin from monoubiquitinated PCNA (<i>p</i>roliferating <i>c</i>ell <i>n</i>uclear <i>a</i>ntigen) [<a class="bk_pop" href="#fa.REF.huang.2006.339">Huang et al 2006</a>]. This may not be coincidental, since FANCD2 and PCNA have been shown to bind [<a class="bk_pop" href="#fa.REF.howlett.2009.28935">Howlett et al 2009</a>]. The deubiquitination event has been shown to be vital for FA function [<a class="bk_pop" href="#fa.REF.oestergaard.2007.798">Oestergaard et al 2007</a>]. Hematopoeitic defects have been noted in knockout mice [<a class="bk_pop" href="#fa.REF.parmar.2010.1186">Parmar et al 2010</a>].</p><p>In nuclear foci, <i>FANCD2</i> colocalizes with <i>FANCI, BRCA1, BRCA2, PALB2</i>, <i>RAD51, BLM, RPA, ATR, FANCC,</i> and <i>FANCE</i> [<a class="bk_pop" href="#fa.REF.garciahiguera.2001.249">Garcia-Higuera et al 2001</a>, <a class="bk_pop" href="#fa.REF.pace.2002.3414">Pace et al 2002</a>, <a class="bk_pop" href="#fa.REF.taniguchi.2002a.2414">Taniguchi et al 2002a</a>, <a class="bk_pop" href="#fa.REF.andreassen.2004.1958">Andreassen et al 2004</a>, <a class="bk_pop" href="#fa.REF.wang.2004.5850">Wang et al 2004</a>, <a class="bk_pop" href="#fa.REF.matsushita.2005.841">Matsushita et al 2005</a>, <a class="bk_pop" href="#fa.REF.xia.2006.719">Xia et al 2006</a>, <a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. FANCD2 also colocalizes partially with BRIP1 [<a class="bk_pop" href="#fa.REF.litman.2005.255">Litman et al 2005</a>] and NBS1 [<a class="bk_pop" href="#fa.REF.nakanishi.2002.913">Nakanishi et al 2002</a>]. All of these factors are required for cellular resistance to DNA cross-linking agents and are considered to work together to repair interstrand DNA cross-links, although the precise mechanism is not understood. Recently, pathogenic variants in <i>RAD51C</i> have been detected in several FA-like cases in a <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> family, also associated with breast and ovarian cancer susceptibility [<a class="bk_pop" href="#fa.REF.meindl.2010.410">Meindl et al 2010</a>, <a class="bk_pop" href="#fa.REF.vaz.2010.406">Vaz et al 2010</a>].</p><p>Among FA proteins, BRCA2 has a clear role in regulating homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> by controlling the activity of RAD51, the eukaryotic homolog of bacterial RecA [<a class="bk_pop" href="#fa.REF.davies.2001.273">Davies et al 2001</a>, <a class="bk_pop" href="#fa.REF.moynahan.2001.263">Moynahan et al 2001</a>]. PALB2 regulates <i>BRCA2</i> stability and localization in nuclear structures (chromatin and nuclear matrix) and, thus, is required for homologous recombination [<a class="bk_pop" href="#fa.REF.xia.2006.719">Xia et al 2006</a>]. The FA core complex, FANCD2, FANCI [<a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>], and BRIP1 [<a class="bk_pop" href="#fa.REF.litman.2005.255">Litman et al 2005</a>] are also reported to be required for efficient homologous recombination, although conflicting reports exist [<a class="bk_pop" href="#fa.REF.taniguchi.2006.4223">Taniguchi &#x00026; D'Andrea 2006</a>].</p><p>FANCD2 protein is also phosphorylated by the ataxia-telangiectasia kinase, ATM, in a process that regulates a radiation-induced S phase checkpoint [<a class="bk_pop" href="#fa.REF.taniguchi.2002b.459">Taniguchi et al 2002b</a>, <a class="bk_pop" href="#fa.REF.ho.2006.7005">Ho et al 2006</a>]. While required for resistance to ionizing radiation, this phosphorylation event is dispensable for cross-linker resistance, implying a separation of or dual function for FANCD2. FANCD2 appears to be phosphorylated by CHK1, which is downstream of ATR, at serine 331 in a manner that results in activation by cross-links [<a class="bk_pop" href="#fa.REF.zhi.2009.8775">Zhi et al 2009</a>].</p><p>Importantly, a number of studies have shown defects in the FA-BRCA pathway to be implicated in cancer:</p><ul><li class="half_rhythm"><div>Individuals with FA are susceptible to both leukemia and solid tumors [<a class="bk_pop" href="#fa.REF.alter.2003">Alter 2003</a>].</div></li><li class="half_rhythm"><div><i>Fancd2</i>, <i>Fanca</i>, or <i>Fancc</i> knockout mice develop tumors [<a class="bk_pop" href="#fa.REF.houghtaling.2003.2021">Houghtaling et al 2003</a>, <a class="bk_pop" href="#fa.REF.wong.2003.2063">Wong et al 2003</a>, <a class="bk_pop" href="#fa.REF.carreau.2004.2430">Carreau 2004</a>].</div></li><li class="half_rhythm"><div>Inactivation of the FA pathway by somatic <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> of <i>FANCF</i> has been found in a wide variety of human cancers (ovarian, breast, non-small cell lung, cervical, testicular, and head and neck squamous cell cancers) in the general population [<a class="bk_pop" href="#fa.REF.olopade.2003.417">Olopade &#x00026; Wei 2003</a>, <a class="bk_pop" href="#fa.REF.taniguchi.2003.568">Taniguchi et al 2003</a>, <a class="bk_pop" href="#fa.REF.marsit.2004.1000">Marsit et al 2004</a>, <a class="bk_pop" href="#fa.REF.narayan.2004.2994">Narayan et al 2004</a>, <a class="bk_pop" href="#fa.REF.wang.2006.256">Wang et al 2006</a>].</div></li><li class="half_rhythm"><div>Inherited and somatic variants of <i>FANCC</i> and <i>FANCG</i> are present in a subset of young-onset pancreatic cancers [<a class="bk_pop" href="#fa.REF.van_der_heijden.2003.2585">van der Heijden et al 2003</a>].</div></li><li class="half_rhythm"><div><i>BRCA1</i> and <i>BRCA2</i> are well-known tumor suppressor genes responsible for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> breast/ovarian cancer [<a class="bk_pop" href="#fa.REF.turner.2004.814">Turner et al 2004</a>].</div></li><li class="half_rhythm"><div>Pathogenic truncating variants in the FA-related genes <i>BRIP1</i> and <i>PALB2</i> are breast cancer susceptibility alleles [<a class="bk_pop" href="#fa.REF.seal.2006.1239">Seal et al 2006</a>, <a class="bk_pop" href="#fa.REF.erkko.2007.316">Erkko et al 2007</a>, <a class="bk_pop" href="#fa.REF.rahman.2007.165">Rahman et al 2007</a>, <a class="bk_pop" href="#fa.REF.tischkowitz.2007.6788">Tischkowitz et al 2007</a>].</div></li></ul><p>Amelioration of FA pathology has been implicated in reports of downregulation of elements of the non-homologous end-joining pathway [<a class="bk_pop" href="#fa.REF.adamo.2010.25">Adamo et al 2010</a>]. These data propose that much of FA pathophysiology results from the unfettered work of NHEJ promoting inaccurate repair. On the other hand, FA involvement in homologous recombinatorial repair has been well established in interactions with BRCA1, BRCA2, and RAD51C. FANCD2 has also been shown to interact with PCNA and pol K, suggesting that translesion synthesis, a variant of homologous recombinantion, may be the most direct function of FA proteins in bypass of the lesion [<a class="bk_pop" href="#fa.REF.ho.2010.552">Ho &#x00026; Sch&#x000e4;rer 2010</a>, <a class="bk_pop" href="#fa.REF.song.2010.31525">Song et al 2010</a>].</p><p>For reviews of the molecular biology of FA, see <a class="bk_pop" href="#fa.REF.nakanishi.2011.500">Nakanishi et al [2011]</a>, <a class="bk_pop" href="#fa.REF.williams.2011b.4395">Williams et al [2011b]</a>, <a class="bk_pop" href="#fa.REF.crossan.2012.326">Crossan &#x00026; Patel [2012]</a>, <a class="bk_pop" href="#fa.REF.kim.2012.1393">Kim &#x00026; D'Andrea [2012]</a>, and <a class="bk_pop" href="#fa.REF.huang.2014.1849">Huang et al [2014]</a>.</p><div id="fa.BRCA2_previously_FANCD1"><h4><i>BRCA2</i> (previously <i>FANCD1</i>)</h4><p><b>Gene structure.</b>
<i>BRCA2</i> has 27 exons (<a href="/nuccore/119395733?" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000059.3</a>).</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The breast cancer type 2 susceptibility protein (BRCA2) has 3418 amino acids. BRCA2 regulates homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> repair through control of RAD51 recombinase [<a class="bk_pop" href="#fa.REF.davies.2001.273">Davies et al 2001</a>, <a class="bk_pop" href="#fa.REF.moynahan.2001.263">Moynahan et al 2001</a>]. Other functions of BRCA2 include stabilizing stalled replication forks and regulating cytokinesis [<a class="bk_pop" href="#fa.REF.daniels.2004.876">Daniels et al 2004</a>]. BRCA2 works in concert with RAD51 to orchestrate the repair of double-strand break ends, prompting the nucleation of each end by RAD51. BRCA2 has been found in various subcomplexes with other FA proteins, including FANCG, FANCD2, and PALB2 [<a class="bk_pop" href="#fa.REF.xia.2007.159">Xia et al 2007</a>, <a class="bk_pop" href="#fa.REF.wilson.2010.12">Wilson et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.BRIP1_previously_FANCJ_or_BACH1"><h4><i>BRIP1</i> (previously <i>FANCJ</i> or <i>BACH1</i>)</h4><p><b>Gene structure.</b>
<i>BRIP1</i> (<a href="/nuccore/NM_032043.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_032043.2</a>) has 20 exons.</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The Fanconi anemia group J protein (BRIP1 or FANCJ) has 1249 amino acids and is a DNA-dependent ATPase and a 5'-to-3' DNA helicase (DEAH helicase) that binds directly to the BRCT <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of BRCA1 [<a class="bk_pop" href="#fa.REF.cantor.2001.149">Cantor et al 2001</a>, <a class="bk_pop" href="#fa.REF.chen.2014.25774">Chen et al 2014</a>, <a class="bk_pop" href="#fa.REF.zou.2014.3685">Zou et al 2014</a>]. FANCJ acetylation regulates DNA damage response [<a class="bk_pop" href="#fa.REF.xie.2012.e1002786">Xie et al 2012</a>], and it contains the seven helicase-specific motifs and C-terminal extension, which has 39% homology with synaptonemal complex protein 1, a major component of the transverse filaments of developing meiotic chromosomes [<a class="bk_pop" href="#fa.REF.cantor.2001.149">Cantor et al 2001</a>, <a class="bk_pop" href="#fa.REF.wu.2012.21699">Wu et al 2012</a>, <a class="bk_pop" href="#fa.REF.brosh.2014.372">Brosh &#x00026; Cantor 2014</a>, <a class="bk_pop" href="#fa.REF.sommers.2014.19928">Sommers et al 2014</a>]. FANCJ engages stable G4/G-quadruplex structures [<a class="bk_pop" href="#fa.REF.sarkies.2012.1485">Sarkies et al 2012</a>, <a class="bk_pop" href="#fa.REF.castillo_bosch.2014.2521">Castillo Bosch et al 2014</a>], promotes stability of FAND2/FANCI [<a class="bk_pop" href="#fa.REF.zhang.2010.637">Zhang et al 2010</a>, <a class="bk_pop" href="#fa.REF.clark.2015.28816">Clark et al 2015</a>], and its helicase domain clearly is important for FA pathway function [<a class="bk_pop" href="#fa.REF.wu.2009.470">Wu &#x00026; Brosh 2009</a>, <a class="bk_pop" href="#fa.REF.guo.2014.10551">Guo et al 2014</a>]. FANCJ also appears to interdigitate with the <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> pathway in binding to MLH1 [<a class="bk_pop" href="#fa.REF.cantor.2010.500">Cantor &#x00026; Xie 2010</a>] and centrosome amplification [<a class="bk_pop" href="#fa.REF.zou.2013.1022">Zou et al 2013</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCA"><h4><i>FANCA</i></h4><p><b>Gene structure.</b> The longest transcript variant <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=66880552" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000135.2</a> has 43 exons.</p><p><b>Pathogenic variants.</b> The pathogenic variants of <i>FANCA</i> are numerous and highly variable among families [<a class="bk_pop" href="#fa.REF.levran.1997.13051">Levran et al 1997</a>, <a class="bk_pop" href="#fa.REF.morgan.1999.1330">Morgan et al 1999</a>, <a class="bk_pop" href="#fa.REF.wijker.1999.52">Wijker et al 1999</a>]. A small percentage of families share the pathogenic variants p.Phe1263del and p.Val372AlafsTer42; the latter is found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of northern European ancestry. See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><div id="fa.T.selected_fanca_pathogenic_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>FANCA</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.selected_fanca_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.selected_fanca_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1115_1118del</td><td headers="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val372AlafsTer42</td><td headers="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000135.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000135<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/66880553" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000126<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3788_3790del</td><td headers="hd_h_fa.T.selected_fanca_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe1263del</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCA encoded by <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=66880552" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000135.2</a> has 1455 amino acids and is a component of the FA core complex. FANCA contains two overlapping bipartite nuclear localization signals (NLS), five functional leucine-rich nuclear export sequences, and a partial leucine zipper sequence [<a class="bk_pop" href="#fa.REF.fanconi_anaemiabreast_cancer_consortium.1996.324">Fanconi Anaemia/Breast Cancer Consortium 1996</a>, <a class="bk_pop" href="#fa.REF.lo_ten_foe.1996.320">Lo Ten Foe et al 1996</a>, <a class="bk_pop" href="#fa.REF.ferrer.2005.1271">Ferrer et al 2005</a>]. The nuclear export of FANCA is regulated in a CRM1-dependent manner [<a class="bk_pop" href="#fa.REF.ferrer.2005.1271">Ferrer et al 2005</a>]. FANCA is a phosphoprotein, a client of Hsp90 [<a class="bk_pop" href="#fa.REF.oda.2007.5016">Oda et al 2007</a>]; it is phosphorylated by the ATR kinase at serine 1449 [<a class="bk_pop" href="#fa.REF.collins.2009.2181">Collins et al 2009</a>]. Reports show that FANCA interacts with FA binding protein FAAP20 [<a class="bk_pop" href="#fa.REF.ali.2012.3285">Ali et al 2012</a>, <a class="bk_pop" href="#fa.REF.leung.2012.4491">Leung et al 2012</a>], is co-regulated with BRCA1 [<a class="bk_pop" href="#fa.REF.haitjema.2014.381">Haitjema et al 2014</a>], and its <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> dysregulates murine T regulatory cells [<a class="bk_pop" href="#fa.REF.du.2014.1938">Du et al 2014</a>]. With FANCC it modulates the toll-like receptor pathway [<a class="bk_pop" href="#fa.REF.garbati.2013.3197">Garbati et al 2013</a>] and &#x02013; critically &#x02013; safeguards cell cycle integrity in hematopoietic cells [<a class="bk_pop" href="#fa.REF.abdulsater.2015.1031">Abdul-Sater et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCB"><h4><i>FANCB</i></h4><p><b>Gene structure.</b>
<i>FANCB</i> has ten exons with the translation start in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 (<a href="/nuccore/66528784?" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001018113.1</a>).</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCB comprises 853 amino acids; some sequences have 859 residues, depending on the initiating methionine. FANCB is a component of the FA core complex and contains a putative bipartite NLS [<a class="bk_pop" href="#fa.REF.meetei.2004.1219">Meetei et al 2004</a>]. FANCB is relevant to normal development &#x02013; as is evidenced by its dysfunction being linked to VACTERL association [<a class="bk_pop" href="#fa.REF.mccauley.2011.2370">McCauley et al 2011</a>, <a class="bk_pop" href="#fa.REF.uma_a.2011.3071">Uma&#x000f1;a et al 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCC"><h4><i>FANCC</i></h4><p><b>Gene structure.</b>
<i>FANCC</i> has 15 exons.</p><p><b>Pathogenic variants.</b> Three common pathogenic variants in <i>FANCC</i> have been identified (c.456+4A&#x0003e;T, c.1642C&#x0003e;T, and c.67delG) [<a class="bk_pop" href="#fa.REF.whitney.1993.202">Whitney et al 1993</a>]. See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><div id="fa.T.selected_fancc_pathogenic_variants" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>FANCC</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.selected_fancc_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.selected_fancc_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.456+4A&#x0003e;T&#x000a0;<sup>2,&#x000a0;3</sup><br />(IVS4+4A&#x0003e;T)</td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=56118235" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000136<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/56118236" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000127<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.37C&#x0003e;T&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln13Ter</td></tr><tr><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.67delG&#x000a0;<sup>4,&#x000a0;5</sup><br />(322delG)</td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp23IlefsTer23</td></tr><tr><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1642C&#x0003e;T&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg548Ter</td></tr><tr><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1661T&#x0003e;C&#x000a0;<sup>3</sup></td><td headers="hd_h_fa.T.selected_fancc_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu554Pro</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="fa.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="fa.TF.4.2"><p class="no_margin">Found primarily in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population; but also reported in a Japanese cohort.</p></div></dd><dt>3. </dt><dd><div id="fa.TF.4.3"><p class="no_margin">See <a href="#fa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd><dt>4. </dt><dd><div id="fa.TF.4.4"><p class="no_margin">Prevalent in individuals of northern European ancestry</p></div></dd><dt>5. </dt><dd><div id="fa.TF.4.5"><p class="no_margin">Found in individuals from southern Italy</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCC has 558 amino acids. It is a component of the FA core complex, but localizes to both the nucleus and the cytoplasm [<a class="bk_pop" href="#fa.REF.yamashita.1994.6712">Yamashita et al 1994</a>]. Some functions of FANCC outside of the FA core complex have also been proposed [<a class="bk_pop" href="#fa.REF.fagerlie.2004.3863">Fagerlie et al 2004</a>]. Reports suggest that STAT1 binds to FANCC to modulate JAK-STAT signaling and to protect cells from interferon gamma toxic effects [<a class="bk_pop" href="#fa.REF.pang.2000.4724">Pang et al 2000</a>, <a class="bk_pop" href="#fa.REF.fagerlie.2004.3863">Fagerlie et al 2004</a>]. Further, FANCC binds to microtubule-associated protein stathmin-1 to regulate cytokinesis [<a class="bk_pop" href="#fa.REF.magron.2015.e0140612">Magron et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCD2"><h4><i>FANCD2</i></h4><p><b>Gene structure.</b>
<i>FANCD2</i> has two transcript variants. Variant 1 (<a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=66528797" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_033084.3</a>) has 43 exons; variant 2 (<a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=66528887" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001018115.1</a>) has 44 exons and an alternate 3' coding sequence resulting in a shorter and distinct C-terminus. FANCD2 protein encoded by variant 2 (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 44 form) is the functional FANCD2 protein, while the other transcript variant encodes a non-functional protein [<a class="bk_pop" href="#fa.REF.montes_de_oca.2005.1003">Montes de Oca et al 2005</a>].</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The functional FANCD2 (<a href="/protein/NP_001018125.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001018125.1</a>) has 1451 amino acids (isoform b) and shares sequence similarity with FANCI. FANCD2 and FANCI form a protein complex (ID complex). FANCD2 can be monoubiquitinated on lysine 561 in an FA core complex-, UBE2T- (also known as FANCT [<a class="bk_pop" href="#fa.REF.hira.2015.1001">Hira et al 2015</a>, <a class="bk_pop" href="#fa.REF.rickman.2015.35">Rickman et al 2015</a>, <a class="bk_pop" href="#fa.REF.virts.2015.5093">Virts et al 2015</a>]), and FANCI-dependent manner [<a class="bk_pop" href="#fa.REF.sato.2012.4553">Sato et al 2012</a>, <a class="bk_pop" href="#fa.REF.rajendra.2014.858">Rajendra et al 2014</a>]. Reports illuminated the structure of FANCI-FAND2 complex [<a class="bk_pop" href="#fa.REF.joo.2011.312">Joo et al 2011</a>], its coordinate nuclear targeting [<a class="bk_pop" href="#fa.REF.boisvert.2013.e81387">Boisvert et al 2013</a>], and its RAD18-mediated chromatin loading [<a class="bk_pop" href="#fa.REF.song.2010.31525">Song et al 2010</a>, <a class="bk_pop" href="#fa.REF.williams.2011a.5078">Williams et al 2011a</a>]. Monoubiquitinated FANCD2 is translocated to chromatin fraction &#x02013; recruited by UHRF1 [<a class="bk_pop" href="#fa.REF.liang.2015.1947">Liang et al 2015</a>] &#x02013; to form nuclear foci with FANCI, BRCA1 (FANCS [<a class="bk_pop" href="#fa.REF.sawyer.2015.135">Sawyer et al 2015</a>]), BRCA2, RAD51, and other partners. FANCD2 can be phosphorylated by ATM [<a class="bk_pop" href="#fa.REF.taniguchi.2002b.459">Taniguchi et al 2002b</a>, <a class="bk_pop" href="#fa.REF.ho.2006.7005">Ho et al 2006</a>] and by ATR [<a class="bk_pop" href="#fa.REF.andreassen.2004.1958">Andreassen et al 2004</a>, <a class="bk_pop" href="#fa.REF.pichierri.2004.1178">Pichierri &#x00026; Rosselli 2004</a>] in response to DNA damage. FANCD2 is phosphorylated at serine 331 by CHK1 in a manner that is required for binding to BRCA2 [<a class="bk_pop" href="#fa.REF.zhi.2009.8775">Zhi et al 2009</a>]. Important studies have shown FANCD2 to have a function in resection of ends surrounding a cross-link in the repair process [<a class="bk_pop" href="#fa.REF.knipscheer.2009.1698">Knipscheer et al 2009</a>], in replication fork processes [<a class="bk_pop" href="#fa.REF.zhu.2015b.1809">Zhu et al 2015b</a>], binding to mini-<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> maintenance proteins in control of replisome [<a class="bk_pop" href="#fa.REF.lossaint.2013.678">Lossaint et al 2013</a>]. A nuclease, FAN1, has been demonstrated to bind to FANCD2 [<a class="bk_pop" href="#fa.REF.huang.2010.926">Huang &#x00026; D'Andrea 2010</a>, <a class="bk_pop" href="#fa.REF.kratz.2010.77">Kratz et al 2010</a>, <a class="bk_pop" href="#fa.REF.mackay.2010.65">MacKay et al 2010</a>], and to promote DNA interstrand cross-link repair [<a class="bk_pop" href="#fa.REF.smogorzewska.2010.36">Smogorzewska et al 2010</a>, <a class="bk_pop" href="#fa.REF.yoshikiyo.2010.21553">Yoshikiyo et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCE"><h4><i>FANCE</i></h4><p><b>Gene structure.</b>
<i>FANCE</i> has 14 exons (<a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=66879667" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_021922.2</a>).</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCE has 536 amino acids and is a component of the FA core complex. FANCE directly binds to FANCD2 and recruits it to the FA E3 ligase complex [<a class="bk_pop" href="#fa.REF.polito.2014.7003">Polito et al 2014</a>]. FANCE contains two nuclear localization signals (NLS) and its nuclear accumulation depends on FANCC [<a class="bk_pop" href="#fa.REF.l_veill_.2006.556">L&#x000e9;veill&#x000e9; et al 2006</a>]. FANCE has five tandem repeats of a short helical motif (FANC repeats) [<a class="bk_pop" href="#fa.REF.nookala.2007.1638">Nookala et al 2007</a>]. It functions as a shuttle protein between the FA core complex and FANCD2 in a fashion dependent on phosphorylation [<a class="bk_pop" href="#fa.REF.wang.2007.3098">Wang et al 2007</a>], with functionality dependent on alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#fa.REF.bouffard.2015.3056">Bouffard et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCF"><h4><i>FANCF</i></h4><p><b>Gene structure.</b>
<i>FANCF</i> has a single <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> (<a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=42716285" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_022725.2</a>).</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCF has 374 amino acids and is a component of the FA core complex. FANCF acts as a flexible adaptor protein required for the assembly of the FA core complex [<a class="bk_pop" href="#fa.REF.l_veill_.2004.39421">L&#x000e9;veill&#x000e9; et al 2004</a>]. Crystallographic studies of the C-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> revealed a helical repeat structure similar to the Cand1 regulator of the Cul1-Rbx1-Skp1-Fbox(Skp2) ubiquitin ligase complex [<a class="bk_pop" href="#fa.REF.kowal.2007.2047">Kowal et al 2007</a>], and &#x02013; recently &#x02013; <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> refined <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> [<a class="bk_pop" href="#fa.REF.nicchia.2015.1003">Nicchia et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCG"><h4><i>FANCG</i></h4><p><b>Gene structure.</b>
<i>FANCG</i> has 14 exons (reference sequence <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=4759335" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004629.1</a>).</p><p><b>Pathogenic variants.</b> Pathogenic variants in <i>FANCG</i> are highly variable, but more common variant alleles have been described in specific populations: c.307+1G&#x0003e;C (Korean/Japanese), c.925-2A&#x0003e;G (Brazilian), c.1480+1G&#x0003e;C (French Canadian), and p.Gly395TrpfsTer5 [<a class="bk_pop" href="#fa.REF.demuth.2000.861">Demuth et al 2000</a>] and p.Trp599ProfsTer49 [<a class="bk_pop" href="#fa.REF.auerbach.2003.158">Auerbach et al 2003</a>] (northern European). See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><div id="fa.T.selected_fancg_pathogenic_variants" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Selected <i>FANCG</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.selected_fancg_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.selected_fancg_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.307+1G&#x0003e;C<br />(IVS3+1G&#x0003e;C)</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/4759335" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004629<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/protein/4759336" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004620<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.925-2A&#x0003e;G<br />(IVS8-2A&#x0003e;G)</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1183-1192del<br />(1184-1194del)</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu395TrpfsTer5</td></tr><tr><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1480+1G&#x0003e;C<br />(IVS11+1G&#x0003e;C)</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp599ProfsTer49</td></tr><tr><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1794_1803del</td><td headers="hd_h_fa.T.selected_fancg_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="fa.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCG has 622 amino acids. It is a component of the FA core complex. FANCG has seven tetratricopeptide repeat motifs [<a class="bk_pop" href="#fa.REF.blom.2004.77">Blom et al 2004</a>, <a class="bk_pop" href="#fa.REF.wilson.2010.12">Wilson et al 2010</a>]. FANCG is a phosphoprotein; serines 383 and 387 on FANCG are phosphorylated in M phase, presumably by cdc2 [<a class="bk_pop" href="#fa.REF.mi.2004.8576">Mi et al 2004</a>]. These two sites are important for exclusion of FANCG from chromatin in mitosis. Phosphorylation of serine 7 of FANCG is upregulated after MMC treatment [<a class="bk_pop" href="#fa.REF.qiao.2004.46035">Qiao et al 2004</a>]. FANCA and FANCG stabilize each other, and FANCG, BRCA2, FANCD2, and XRCC3 participate in the same protein complex. This implies multifunctionality of FANCG by its presence in the core complex as well as in homologous recombinatorial repair [<a class="bk_pop" href="#fa.REF.wang.2007.3098">Wang et al 2007</a>]. FANCG further associates with Rap80-BRCA1 complex in DNA repair mediated by homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> [<a class="bk_pop" href="#fa.REF.zhu.2015a.2867">Zhu et al 2015a</a>], and it is operational in homing of hematopoietic stem cells [<a class="bk_pop" href="#fa.REF.barroca.2012.121">Barroca et al 2012</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p></div><div id="fa.FANCI"><h4><i>FANCI</i></h4><p><b>Gene structure.</b>
<i>FANCI</i> has 37 exons (<a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=82830439" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_018193.2</a>).</p><p><b>Pathogenic variants.</b> See <a href="/books/NBK1401/#fa.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> FANCI has 1268 amino acids and shares sequence similarity with FANCD2. FANCD2 and FANCI form a protein complex (ID complex). FANCI can be monoubiquitinated on lysine 523 in an FA core complex-, UBE2T-, and FANCD2-dependent manner. Monoubiquitinated FANCI is translocated to nuclear foci and colocalizes with BRCA1, BRCA2, RAD51, FANCD2 [<a class="bk_pop" href="#fa.REF.boisvert.2014.2999">Boisvert &#x00026; Howlett 2014</a>, <a class="bk_pop" href="#fa.REF.rajendra.2014.858">Rajendra et al 2014</a>]. FANCI is a phosphoprotein. DNA damage-induced phosphorylation of p.Ser730, p.Thr952, and p.Ser1121 of human FANCI can be detected [<a class="bk_pop" href="#fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. FANCI functions in an analogous manner as FANCD2 and can be analyzed in the same fashion in assays including DNA repair foci, cell survival, and monoubiquitination [<a class="bk_pop" href="#fa.REF.ishiai.2008.1138">Ishiai et al 2008</a>]. Reports illuminated the structure of FANCI-FAND2 complex [<a class="bk_pop" href="#fa.REF.joo.2011.312">Joo et al 2011</a>], its coordinate nuclear targeting [<a class="bk_pop" href="#fa.REF.boisvert.2013.e81387">Boisvert et al 2013</a>], and &#x02013; remarkably &#x02013; its FANCD2-independent function upstream of FA core complex recruitment [<a class="bk_pop" href="#fa.REF.castella.2015.e1005563">Castella et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#fa.Molecular_Pathogenesis">Molecular Pathogenesis</a>.</p><p>Click <a href="/books/NBK1401/bin/fa-less_common_genes.pdf">here</a> (pdf) for information on the genes less commonly involved in Fanconi Anemia (from <a class="figpopup" href="/books/NBK1401/table/fa.T.molecular_genetics_of_fanconi_anemi_1/?report=objectonly" target="object" rid-figpopup="figfaTmoleculargeneticsoffanconianemi1" rid-ob="figobfaTmoleculargeneticsoffanconianemi1">Table 1b</a>).</p></div></div></div><div id="fa.References"><h2 id="_fa_References_">References</h2><div id="fa.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fa.REF.abdulsater.2015.1031">Abdul-Sater Z, Cerabona D, Potchanant ES, Sun Z, Enzor R, He Y, Robertson K, Goebel WS, Nalepa G. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. <span><span class="ref-journal">Exp Hematol. </span>2015;<span class="ref-vol">43</span>:1031–46.e12.</span> [<a href="/pmc/articles/PMC4666759/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4666759</span></a>] [<a href="/pubmed/26366677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26366677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.adamo.2010.25">Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, Martinez-Perez E, Boulton SJ, La Volpe A. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. <span><span class="ref-journal">Mol Cell. </span>2010;<span class="ref-vol">39</span>:25–35.</span> [<a href="/pubmed/20598602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20598602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ali.2012.3285">Ali AM, Pradhan A, Singh TR, Du C, Li J, Wahengbam K, Grassman E, Auerbach AD, Pang Q, Meetei AR. FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>:3285–94.</span> [<a href="/pmc/articles/PMC3321854/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3321854</span></a>] [<a href="/pubmed/22343915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22343915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.alpi.2008.767">Alpi AF, Pace PE, Babu MM, Patel KJ. Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. <span><span class="ref-journal">Mol Cell. </span>2008;<span class="ref-vol">32</span>:767–77.</span> [<a href="/pubmed/19111657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19111657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.alter.2003">Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. <em>Nathan and Oski's Hematology of Infancy and Childhood</em>. 6 ed. Philadelphia, PA: WB Saunders; 2003:280-365.</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.alter.2006.446">Alter BP. The association between FANCD1/BRCA2 mutations and leukaemia. <span><span class="ref-journal">Br J Haematol. </span>2006;<span class="ref-vol">133</span>:446–8.</span> [<a href="/pubmed/16643458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16643458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.alter.2010.179">Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L, Carr AG, Greene MH, Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">150</span>:179–88.</span> [<a href="/pmc/articles/PMC3125983/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3125983</span></a>] [<a href="/pubmed/20507306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20507306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.alter.2007.1">Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:1–9.</span> [<a href="/pmc/articles/PMC2597904/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2597904</span></a>] [<a href="/pubmed/16825431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16825431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ameziane.2015.8829">Ameziane N, May P, Haitjema A, van de Vrugt HJ, van Rossum-Fikkert SE, Ristic D, Williams GJ, Balk J, Rockx D, Li H, Rooimans MA, Oostra AB, Velleuer E, Dietrich R, Bleijerveld OB, Maarten Altelaar AF, Meijers-Heijboer H, Joenje H, Glusman G, Roach J, Hood L, Galas D, Wyman C, Balling R, den Dunnen J, de Winter JP, Kanaar R, Gelinas R, Dorsman JC. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. <span><span class="ref-journal">Nat Commun. </span>2015;<span class="ref-vol">6</span>:8829.</span> [<a href="/pmc/articles/PMC4703882/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4703882</span></a>] [<a href="/pubmed/26681308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26681308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.andreassen.2004.1958">Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. <span><span class="ref-journal">Genes Dev. </span>2004;<span class="ref-vol">18</span>:1958–63.</span> [<a href="/pmc/articles/PMC514175/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC514175</span></a>] [<a href="/pubmed/15314022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15314022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.auerbach.2003.158">Auerbach AD, Greenbaum J, Pujara K, Batish SD, Bitencourt MA, Kokemohr I, Schneider H, Lobitzc S, Pasquini R, Giampietro PF, Hanenberg H, Levran O., International Fanconi Anemia Registry.  Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:158–68.</span> [<a href="/pubmed/12552564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12552564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.barroca.2012.121">Barroca V, Mouthon MA, Lewandowski D, Brunet de la Grange P, Gauthier LR, Pflumio F, Boussin FD, Arwert F, Riou L, Allemand I, Romeo PH, Fouchet P. Impaired functionality and homing of Fancg-deficient hematopoietic stem cells. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:121–35.</span> [<a href="/pubmed/21968513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21968513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.becker.2010.1244">Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, Adair J, Kohn DB, Wagner JE, Shimamura A, Kiem HP. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. <span><span class="ref-journal">Gene Ther. </span>2010;<span class="ref-vol">17</span>:1244–52.</span> [<a href="/pmc/articles/PMC2927804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2927804</span></a>] [<a href="/pubmed/20485382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20485382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.beier.2015.463">Beier R, Maecker-Kolhoff B, Sykora K-W, Chao M, Kratz C, Sauer MG. Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML. <span><span class="ref-journal">Bone Marrow Transplant. </span>2015;<span class="ref-vol">50</span>:463–4.</span> [<a href="/pubmed/25531282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25531282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.berwick.2007.9591">Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. <span><span class="ref-journal">Cancer Res. </span>2007;<span class="ref-vol">67</span>:9591–6.</span> [<a href="/pmc/articles/PMC3622247/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3622247</span></a>] [<a href="/pubmed/17909071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17909071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.blom.2004.77">Blom E, van de Vrugt HJ, de Vries Y, de Winter JP, Arwert F, Joenje H. Multiple TPR motifs characterize the Fanconi anemia FANCG protein. <span><span class="ref-journal">DNA Repair (Amst). </span>2004;<span class="ref-vol">3</span>:77–84.</span> [<a href="/pubmed/14697762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14697762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.bluteau.2016.3580">Bluteau D, Masliah-Planchon J, Clairmont C, Rousseau A, Ceccaldi R, Dubois d'Enghien C, Bluteau O, Cuccuini W, Gachet S, Peffault de Latour R, Leblanc T, Soci&#x000e9; G, Baruchel A, Stoppa-Lyonnet D, D'Andrea AD, Soulier J. Biallelic inactivation of REV7 is associated with Fanconi anemia. <span><span class="ref-journal">J Clin Invest. </span>2016;<span class="ref-vol">126</span>:3580–4.</span> [<a href="/pmc/articles/PMC5004932/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5004932</span></a>] [<a href="/pubmed/27500492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27500492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.bogliolo.2007.1340">Bogliolo M, Lyakhovich A, Call&#x000e9;n E, Castell&#x000e0; M, Cappelli E, Ram&#x000ed;rez MJ, Creus A, Marcos R, Kalb R, Neveling K, Schindler D, Surrall&#x000e9;s J. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. <span><span class="ref-journal">EMBO J. </span>2007;<span class="ref-vol">26</span>:1340–51.</span> [<a href="/pmc/articles/PMC1817623/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1817623</span></a>] [<a href="/pubmed/17304220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17304220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.bogliolo.2013.800">Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, Trujillo JP, Minguill&#x000f3;n J, Ram&#x000ed;rez MJ, Pujol R, Casado JA, Ba&#x000f1;os R, Rio P, Knies K, Z&#x000fa;&#x000f1;iga S, Ben&#x000ed;tez J, Bueren JA, Jaspers NG, Sch&#x000e4;rer OD, de Winter JP, Schindler D, Surrall&#x000e9;s J. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:800–6.</span> [<a href="/pmc/articles/PMC3644630/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644630</span></a>] [<a href="/pubmed/23623386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23623386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.bonfim.2015.s94a">Bonfim C, Riberio L, Nichele S, Loth G, Kuwahara C, Koliski A, Bitencourt M, Scherer F, Rodrigues L, Pilonetto D, Pasquini R. Excellent outcomes for Fanconi anemia patients undergoing hematopoietic stem cell transplantation (HSCT) without radiation: a single center experience on 103 patients. <span><span class="ref-journal">Biol Blood Marrow Transplant. </span>2015;<span class="ref-vol">21</span>:S94a.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.boisvert.2014.2999">Boisvert RA, Howlett NG. The Fanconi anemia ID2 complex: dueling saxes at the crossroads. <span><span class="ref-journal">Cell Cycle. </span>2014;<span class="ref-vol">13</span>:2999–3015.</span> [<a href="/pmc/articles/PMC4612647/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4612647</span></a>] [<a href="/pubmed/25486561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25486561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.boisvert.2013.e81387">Boisvert RA, Rego MA, Azzinaro PA, Mauro M, Howlett NG. Coordinate nuclear targeting of the FANCD2 and FANCI proteins via a FANCD2 nuclear localization signal. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e81387.</span> [<a href="/pmc/articles/PMC3836817/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3836817</span></a>] [<a href="/pubmed/24278431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24278431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.bouffard.2015.3056">Bouffard F, Plourde K, B&#x000e9;langer S, Ouellette G, Labrie Y, Durocher F. Analysis of a FANCE Splice Isoform in Regard to DNA Repair. <span><span class="ref-journal">J Mol Biol. </span>2015;<span class="ref-vol">427</span>:3056–73.</span> [<a href="/pubmed/26277624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26277624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.brosh.2014.372">Brosh RM Jr, Cantor SB. Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia. <span><span class="ref-journal">Front Genet. </span>2014;<span class="ref-vol">5</span>:372.</span> [<a href="/pmc/articles/PMC4204437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4204437</span></a>] [<a href="/pubmed/25374583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25374583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.byrd.2016.e1005945">Byrd PJ, Stewart GS, Smith A, Eaton C, Taylor AJ, Guy C, Eringyte I, Fooks P, Last JI, Horsley R, Oliver AW, Janic D, Dokmanovic L, Stankovic T, Taylor AM. A hypomorphic PALB2 allele gives rise to an unusual form of FA-N associated with lymphoid tumour development. <span><span class="ref-journal">PLoS Genet. </span>2016;<span class="ref-vol">12</span>:e1005945.</span> [<a href="/pmc/articles/PMC4798644/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4798644</span></a>] [<a href="/pubmed/26990772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26990772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.cantor.2001.149">Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">105</span>:149–60.</span> [<a href="/pubmed/11301010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11301010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.cantor.2010.500">Cantor SB, Xie J. Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair. <span><span class="ref-journal">Environ Mol Mutagen. </span>2010;<span class="ref-vol">51</span>:500–7.</span> [<a href="/pubmed/20658644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20658644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.carreau.2004.2430">Carreau M. Not-so-novel phenotypes in the Fanconi anemia group D2 mouse model. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:2430.</span> [<a href="/pubmed/14998919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14998919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.castella.2015.e1005563">Castella M, Jacquemont C, Thompson EL, Yeo JE, Cheung RS, Huang JW, Sobeck A, Hendrickson EA, Taniguchi T. FANCI regulates recruitment of the FA core complex at sites of DNA damage independently of FANCD2. <span><span class="ref-journal">PLoS Genet. </span>2015;<span class="ref-vol">11</span>:e1005563.</span> [<a href="/pmc/articles/PMC4592014/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4592014</span></a>] [<a href="/pubmed/26430909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26430909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.castillo_bosch.2014.2521">Castillo Bosch P, Segura-Bayona S, Koole W, van Heteren JT, Dewar JM, Tijsterman M, Knipscheer P. FANCJ promotes DNA synthesis through G-quadruplex structures. <span><span class="ref-journal">EMBO J. </span>2014;<span class="ref-vol">33</span>:2521–33.</span> [<a href="/pmc/articles/PMC4282361/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4282361</span></a>] [<a href="/pubmed/25193968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25193968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.chao.2015.1311">Chao MM, Kuehl JS, Strauss G, Hanenberg H, Schindler D, Neitzel H, Niemeyer C, Baumann I, von Bernuth H, Rascon J, Nagy M, Zimmermann M, Kratz CP, Ebell W. Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only. <span><span class="ref-journal">Ann Hematol. </span>2015;<span class="ref-vol">94</span>:1311–8.</span> [<a href="/pubmed/25862235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25862235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.chandrasekharappa.2013.e138">Chandrasekharappa SC, Lach FP, Kimble DC, Kamat A, Teer JK, Donovan FX, Flynn E, Sen SK, Thongthip S, Sanborn E, Smogorzewska A, Auerbach AD, Ostrander EA., NISC Comparative Sequencing Program.  Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:e138–48.</span> [<a href="/pmc/articles/PMC3668494/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3668494</span></a>] [<a href="/pubmed/23613520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23613520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.chaudhury.2008.644">Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A, Heller G, Wolden S, O'Reilly RJ, Boulad F. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">140</span>:644–55.</span> [<a href="/pubmed/18302713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18302713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.chen.2014.25774">Chen X, Wilson JB, McChesney P, Williams SA, Kwon Y, Longerich S, Marriott AS, Sung P, Jones NJ, Kupfer GM. The Fanconi anemia proteins FANCD2 and FANCJ interact and regulate each other's chromatin localization. <span><span class="ref-journal">J Biol Chem. </span>2014;<span class="ref-vol">289</span>:25774–82.</span> [<a href="/pmc/articles/PMC4162179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4162179</span></a>] [<a href="/pubmed/25070891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25070891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.chrzanowska.2012.13">Chrzanowska KH, Gregorek H, Dembowska-Bagi&#x00144;ska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:13.</span> [<a href="/pmc/articles/PMC3314554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3314554</span></a>] [<a href="/pubmed/22373003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22373003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ciccia.2007.331">Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR. Laghmani el H, Joenje H, McDonald N, de Winter JP, Wang W, West SC. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. <span><span class="ref-journal">Mol Cell. </span>2007;<span class="ref-vol">25</span>:331–43.</span> [<a href="/pubmed/17289582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17289582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.clark.2015.28816">Clark DW, Tripathi K, Dorsman JC, Palle K. FANCJ protein is important for the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation. <span><span class="ref-journal">Oncotarget. </span>2015;<span class="ref-vol">6</span>:28816–32.</span> [<a href="/pmc/articles/PMC4745694/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4745694</span></a>] [<a href="/pubmed/26336824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26336824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.cohn.2007.786">Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, D'Andrea AD. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. <span><span class="ref-journal">Mol Cell. </span>2007;<span class="ref-vol">28</span>:786–97.</span> [<a href="/pubmed/18082604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18082604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.collins.2009.2181">Collins NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, Jones NJ, Kupfer GM. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">113</span>:2181–90.</span> [<a href="/pmc/articles/PMC2652366/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2652366</span></a>] [<a href="/pubmed/19109555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19109555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.collis.2008.313">Collis SJ, Ciccia A, Deans AJ, Horejs&#x000ed; Z, Martin JS, Maslen SL, Skehel JM, Elledge SJ, West SC, Boulton SJ. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. <span><span class="ref-journal">Mol Cell. </span>2008;<span class="ref-vol">32</span>:313–24.</span> [<a href="/pubmed/18995830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18995830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.collis.2007.391">Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. <span><span class="ref-journal">Nat Cell Biol. </span>2007;<span class="ref-vol">9</span>:391–401.</span> [<a href="/pubmed/17384638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17384638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.crossan.2012.326">Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. <span><span class="ref-journal">J Pathol. </span>2012;<span class="ref-vol">226</span>:326–37.</span> [<a href="/pubmed/21956823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21956823</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.dandrea.2010.1909">D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">362</span>:1909–19.</span> [<a href="/pmc/articles/PMC3069698/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3069698</span></a>] [<a href="/pubmed/20484397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20484397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.dalle.2004.1099">Dalle JH, Huot C, Duval M, Rousseau P, Francoeur D, Champagne J, Vachon MF, Champagne MA. Successful pregnancies after bone marrow transplantation for Fanconi anemia. <span><span class="ref-journal">Bone Marrow Transplant. </span>2004;<span class="ref-vol">34</span>:1099–100.</span> [<a href="/pubmed/15489874" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15489874</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.daniels.2004.876">Daniels MJ, Wang Y, Lee M, Venkitaraman AR. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. <span><span class="ref-journal">Science. </span>2004;<span class="ref-vol">306</span>:876–9.</span> [<a href="/pubmed/15375219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15375219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.davies.2001.273">Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. <span><span class="ref-journal">Mol Cell. </span>2001;<span class="ref-vol">7</span>:273–82.</span> [<a href="/pubmed/11239456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11239456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.deans.2009.943">Deans AJ, West SC. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. <span><span class="ref-journal">Mol Cell. </span>2009;<span class="ref-vol">36</span>:943–53.</span> [<a href="/pubmed/20064461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20064461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.deans.2011.467">Deans AJ, West SC. DNA interstrand crosslink repair and cancer. <span><span class="ref-journal">Nat Rev Cancer. </span>2011;<span class="ref-vol">11</span>:467–80.</span> [<a href="/pmc/articles/PMC3560328/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3560328</span></a>] [<a href="/pubmed/21701511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21701511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.demuth.2000.861">Demuth I, Wlodarski M, Tipping AJ, Morgan NV, de Winter JP, Thiel M, Gr&#x000e4;sl S, Schindler D, D'Andrea AD, Altay C, Kayserili H, Zatterale A, Kunze J, Ebell W, Mathew CG, Joenje H, Sperling K, Digweed M. Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:861–8.</span> [<a href="/pubmed/11093276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11093276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.du.2014.1938">Du W, Erden O, Wilson A, Sipple JM, Schick J, Mehta P, Myers KC, Steinbrecher KA, Davies SM, Pang Q. Deletion of Fanca or Fancd2 dysregulates Treg in mice. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:1938–47.</span> [<a href="/pmc/articles/PMC3962166/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3962166</span></a>] [<a href="/pubmed/24501220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24501220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.erkko.2007.316">Erkko H, Xia B, Nikkil&#x000e4; J, Schleutker J, Syrj&#x000e4;koski K, Mannermaa A, Kallioniemi A, Pylk&#x000e4;s K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">446</span>:316–9.</span> [<a href="/pubmed/17287723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17287723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.fagerlie.2004.3863">Fagerlie SR, Koretsky T, Torok-Storb B, Bagby GC. Impaired type I IFN-induced Jak/STAT signaling in FA-C cells and abnormal CD4+ Th cell subsets in Fancc-/- mice. <span><span class="ref-journal">J Immunol. </span>2004;<span class="ref-vol">173</span>:3863–70.</span> [<a href="/pubmed/15356134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15356134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.faivre.2000.4064">Faivre L, Guardiola P, Lewis C, Dokal I, Ebell W, Zatterale A, Altay C, Poole J, Stones D, Kwee ML, van Weel-Sipman M, Havenga C, Morgan N, de Winter J, Digweed M, Savoia A, Pronk J, de Ravel T, Jansen S, Joenje H, Gluckman E, Mathew CG. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">96</span>:4064–70.</span> [<a href="/pubmed/11110674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11110674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.faivre.2005.55">Faivre L, Portnoi MF, Pals G, Stoppa-Lyonnet D, Le Merrer M, Thauvin-Robinet C, Huet F, Mathew CG, Joenje H, Verloes A, Baumann C. Should chromosome breakage studies be performed in patients with VACTERL association? <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">137</span>:55–8.</span> [<a href="/pubmed/16015582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16015582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.fanconi_anaemiabreast_cancer_consortium.1996.324">Fanconi Anaemia/Breast Cancer Consortium.  Positional cloning of the Fanconi anaemia group A gene. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:324–8.</span> [<a href="/pubmed/8896564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ferrer.2005.1271">Ferrer M, Rodriguez JA, Spierings EA, de Winter JP, Giaccone G, Kruyt FA. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:1271–81.</span> [<a href="/pubmed/15790592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15790592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.frohnmayer.2014">Frohnmayer D, Frohnmayer L, Guinan E, Kennedy T, Larsen K, eds. <em>Fanconi Anemia: Guidelines for Diagnosis and Management.</em> 4 ed. Eugene, OR: Fanconi Anemia Research Fund, Inc. Available <a href="http://fanconi.org/images/uploads/other/FA_Guidelines_4th_Edition_Revised_Names_in_Appendix.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2014. Accessed 3-6-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.futaki.2000.1493">Futaki M, Yamashita T, Yagasaki H, Toda T, Yabe M, Kato S, Asano S, Nakahata T. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">95</span>:1493–8.</span> [<a href="/pubmed/10666230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10666230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.garbati.2013.3197">Garbati MR, Hays LE, Keeble W, Yates JE, Rathbun RK, Bagby GC. FANCA and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1&#x003b2; in macrophages. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">122</span>:3197–205.</span> [<a href="/pmc/articles/PMC3814736/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3814736</span></a>] [<a href="/pubmed/24046015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24046015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.garciahiguera.2001.249">Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. <span><span class="ref-journal">Mol Cell. </span>2001;<span class="ref-vol">7</span>:249.</span> [<a href="/pubmed/11239454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11239454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.gillio.1997.105">Gillio AP, Verlander PC, Batish SD, Giampietro PF, Auerbach AD. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. <span><span class="ref-journal">Blood. </span>1997;<span class="ref-vol">90</span>:105–10.</span> [<a href="/pubmed/9207444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9207444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.giulino.2011.278">Giulino L, Guinan EC, Gillio AP, Drachtman RA, Teruya-Feldstein J, Boulad F. Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">154</span>:278–81.</span> [<a href="/pubmed/21501135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21501135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.guardiola.2004.73">Guardiola P, Soci&#x000e9; G, Li X, Ribaud P, Devergie A, Esp&#x000e9;rou H, Richard P, Traineau R, Janin A, Gluckman E. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:73–7.</span> [<a href="/pubmed/12946993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12946993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.guo.2014.10551">Guo M, Vidhyasagar V, Ding H, Wu Y. Insight into the roles of helicase motif Ia by characterizing Fanconi anemia group J protein (FANCJ) patient mutations. <span><span class="ref-journal">J Biol Chem. </span>2014;<span class="ref-vol">289</span>:10551–65.</span> [<a href="/pmc/articles/PMC4036176/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4036176</span></a>] [<a href="/pubmed/24573678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24573678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.haitjema.2014.381">Haitjema A, Mol BM, Kooi IE, Massink MP, J&#x000f8;rgensen JA, Rockx DA, Rooimans MA, de Winter JP, Meijers-Heijboer H, Joenje H, Dorsman JC. Coregulation of FANCA and BRCA1 in human cells. <span><span class="ref-journal">Springerplus. </span>2014;<span class="ref-vol">3</span>:381.</span> [<a href="/pmc/articles/PMC4143540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4143540</span></a>] [<a href="/pubmed/25161863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25161863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.hira.2015.1001">Hira A, Yoshida K, Sato K, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, Ito E, Kojima S, Kurumizaka H, Ogawa S, Takata M, Yabe H, Yabe M. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. <span><span class="ref-journal">Am J Hum Genet. </span>2015;<span class="ref-vol">96</span>:1001–7.</span> [<a href="/pmc/articles/PMC4457949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4457949</span></a>] [<a href="/pubmed/26046368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26046368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.hirsch.2004.2554">Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-alshiekh M, Bostrom B, Sencer S, D'Andrea AD. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:2554–9.</span> [<a href="/pubmed/14670928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14670928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ho.2006.7005">Ho GP, Margossian S, Taniguchi T, D'Andrea AD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. <span><span class="ref-journal">Mol Cell Biol. </span>2006;<span class="ref-vol">26</span>:7005–15.</span> [<a href="/pmc/articles/PMC1592857/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1592857</span></a>] [<a href="/pubmed/16943440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16943440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ho.2010.552">Ho TV, Sch&#x000e4;rer OD. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. <span><span class="ref-journal">Environ Mol Mutagen. </span>2010;<span class="ref-vol">51</span>:552–66.</span> [<a href="/pubmed/20658647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20658647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.hosoya.2010.805">Hosoya Y, Lefor A, Hirashima Y, Nokubi M, Yamaguti T, Jinbu Y, Muroi K, Nakazawa M, Yasuda Y. Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. <span><span class="ref-journal">Jpn J Clin Oncol. </span>2010;<span class="ref-vol">40</span>:805–10.</span> [<a href="/pubmed/20410055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20410055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.houghtaling.2003.2021">Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, Grompe M. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. <span><span class="ref-journal">Genes Dev. </span>2003;<span class="ref-vol">17</span>:2021–35.</span> [<a href="/pmc/articles/PMC196256/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC196256</span></a>] [<a href="/pubmed/12893777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12893777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.howlett.2002.606">Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. <span><span class="ref-journal">Science. </span>2002;<span class="ref-vol">297</span>:606–9.</span> [<a href="/pubmed/12065746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12065746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.howlett.2009.28935">Howlett NG, Harney JA, Rego MA, Kolling FW 4th, Glover TW. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. <span><span class="ref-journal">J Biol Chem. </span>2009;<span class="ref-vol">284</span>:28935–42.</span> [<a href="/pmc/articles/PMC2781439/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2781439</span></a>] [<a href="/pubmed/19704162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19704162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.huang.2010.926">Huang M, D'Andrea AD. A new nuclease member of the FAN club. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2010;<span class="ref-vol">17</span>:926–8.</span> [<a href="/pmc/articles/PMC2945811/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2945811</span></a>] [<a href="/pubmed/20683477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20683477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.huang.2010.259">Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD. The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. <span><span class="ref-journal">Mol Cell. </span>2010;<span class="ref-vol">39</span>:259–68.</span> [<a href="/pmc/articles/PMC2928996/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2928996</span></a>] [<a href="/pubmed/20670894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20670894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.huang.2014.1849">Huang Y, Leung JW, Lowery M, Matsushita N, Wang Y, Shen X, Huong D, Takata M, Chen J, Li L. Modularized functions of the Fanconi anemia core complex. <span><span class="ref-journal">Cell Rep. </span>2014;<span class="ref-vol">7</span>:1849–57.</span> [<a href="/pmc/articles/PMC4157997/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4157997</span></a>] [<a href="/pubmed/24910428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24910428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.huang.2006.339">Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R, D'Andrea AD. Regulation of monoubiquitinated PCNA by DUB autocleavage. <span><span class="ref-journal">Nat Cell Biol. </span>2006;<span class="ref-vol">8</span>:339–47.</span> [<a href="/pubmed/16531995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16531995</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ishiai.2008.1138">Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, Saberi A, Kinoshita E, Kinoshita-Kikuta E, Koike T, Tashiro S, Elledge SJ, Takata M. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2008;<span class="ref-vol">15</span>:1138–46.</span> [<a href="/pmc/articles/PMC3293454/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3293454</span></a>] [<a href="/pubmed/18931676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18931676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.jones.2009.217">Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">324</span>:217.</span> [<a href="/pmc/articles/PMC2684332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2684332</span></a>] [<a href="/pubmed/19264984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19264984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.joo.2011.312">Joo W, Xu G, Persky NS, Smogorzewska A, Rudge DG, Buzovetsky O, Elledge SJ, Pavletich NP. Structure of the FANCI-FANCD2 complex: insights into the Fanconi anemia DNA repair pathway. <span><span class="ref-journal">Science. </span>2011;<span class="ref-vol">333</span>:312–6.</span> [<a href="/pmc/articles/PMC3310437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3310437</span></a>] [<a href="/pubmed/21764741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21764741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kahraman.2014.340">Kahraman S, Beyazyurek C, Yesilipek MA, Ozturk G, Ertem M, Anak S, Kansoy S, Aksoylar S, Ku&#x0015f;konmaz B, Oniz H, Slavin S, Karakas Z, Tac HA, Gulum N, Ekmekci GC. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. <span><span class="ref-journal">Reprod Biomed Online. </span>2014;<span class="ref-vol">29</span>:340–51.</span> [<a href="/pubmed/25066893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25066893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kee.2012.3799">Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. <span><span class="ref-journal">J Clin Invest. </span>2012;<span class="ref-vol">122</span>:3799–806.</span> [<a href="/pmc/articles/PMC3484428/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3484428</span></a>] [<a href="/pubmed/23114602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23114602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kim.2012.1393">Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. <span><span class="ref-journal">Genes Dev. </span>2012;<span class="ref-vol">26</span>:1393–408.</span> [<a href="/pmc/articles/PMC3403008/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3403008</span></a>] [<a href="/pubmed/22751496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22751496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kim.2011.142">Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:142–6.</span> [<a href="/pmc/articles/PMC3345287/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3345287</span></a>] [<a href="/pubmed/21240275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21240275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.knies.2017.3013">Knies K, Inano S, Ram&#x000ed;rez MJ, Ishiai M, Surrall&#x000e9;s J, Takata M, Schindler D. Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia. <span><span class="ref-journal">J Clin Invest. </span>2017;<span class="ref-vol">127</span>:3013–27.</span> [<a href="/pmc/articles/PMC5531404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5531404</span></a>] [<a href="/pubmed/28691929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28691929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.knipscheer.2009.1698">Knipscheer P, R&#x000e4;schle M, Smogorzewska A, Enoiu M, Ho TV, Sch&#x000e4;rer OD, Elledge SJ, Walter JC. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">326</span>:1698–701.</span> [<a href="/pmc/articles/PMC2909596/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2909596</span></a>] [<a href="/pubmed/19965384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19965384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kowal.2007.2047">Kowal P, Gurtan AM, Stuckert P, D'Andrea AD, Ellenberger T. Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. <span><span class="ref-journal">J Biol Chem. </span>2007;<span class="ref-vol">282</span>:2047–55.</span> [<a href="/pubmed/17082180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17082180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kratz.2010.77">Kratz K, Sch&#x000f6;pf B, Kaden S, Sendoel A, Eberhard R, Lademann C, Cannav&#x000f3; E, Sartori AA, Hengartner MO, Jiricny J. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. <span><span class="ref-journal">Cell. </span>2010;<span class="ref-vol">142</span>:77–88.</span> [<a href="/pubmed/20603016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20603016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.kutler.2003.1249">Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:1249–56.</span> [<a href="/pubmed/12393516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12393516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.leung.2012.4491">Leung JW, Wang Y, Fong KW, Huen MS, Li L, Chen J. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2012;<span class="ref-vol">109</span>:4491–6.</span> [<a href="/pmc/articles/PMC3311328/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3311328</span></a>] [<a href="/pubmed/22396592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22396592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.l_veill_.2004.39421">L&#x000e9;veill&#x000e9; F, Blom E, Medhurst AL, Bier P. Laghmani el H, Johnson M, Rooimans MA, Sobeck A, Waisfisz Q, Arwert F, Patel KJ, Hoatlin ME, Joenje H, de Winter JP. The Fanconi anemia gene product FANCF is a flexible adaptor protein. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:39421–30.</span> [<a href="/pubmed/15262960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15262960</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.l_veill_.2006.556">L&#x000e9;veill&#x000e9; F, Ferrer M, Medhurst AL. Laghmani el H, Rooimans MA, Bier P, Steltenpool J, Titus TA, Postlethwait JH, Hoatlin ME, Joenje H, de Winter JP. The nuclear accumulation of the Fanconi anemia protein FANCE depends on FANCC. <span><span class="ref-journal">DNA Repair (Amst). </span>2006;<span class="ref-vol">5</span>:556–65.</span> [<a href="/pubmed/16513431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16513431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.levitus.2005.934">Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, De Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:934–5.</span> [<a href="/pubmed/16116423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.levran.2005.931">Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, Ott J, Petrini J, Schindler D, Hanenberg H, Auerbach AD. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:931–3.</span> [<a href="/pubmed/16116424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.levran.1997.13051">Levran O, Erlich T, Magdalena N, Gregory JJ, Batish SD, Verlander PC, Auerbach AD. Sequence variation in the Fanconi anemia gene FAA. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1997;<span class="ref-vol">94</span>:13051–6.</span> [<a href="/pmc/articles/PMC24261/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC24261</span></a>] [<a href="/pubmed/9371798" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371798</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.liang.2015.1947">Liang CC, Zhan B, Yoshikawa Y, Haas W, Gygi SP, Cohn MA. UHRF1 is a sensor for DNA interstrand crosslinks and recruits FANCD2 to initiate the Fanconi anemia pathway. <span><span class="ref-journal">Cell Rep. </span>2015;<span class="ref-vol">10</span>:1947–56.</span> [<a href="/pmc/articles/PMC4386029/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4386029</span></a>] [<a href="/pubmed/25801034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25801034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.ling.2007.2104">Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Takata M, Meetei AR, Wang W. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. <span><span class="ref-journal">EMBO J. </span>2007;<span class="ref-vol">26</span>:2104–14.</span> [<a href="/pmc/articles/PMC1852792/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1852792</span></a>] [<a href="/pubmed/17396147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17396147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.litman.2005.255">Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. <span><span class="ref-journal">Cancer Cell. </span>2005;<span class="ref-vol">8</span>:255–65.</span> [<a href="/pubmed/16153896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16153896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.lo_ten_foe.1996.320">Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, Cheng NC, van Berkel CG, Strunk MH, Gille JJ, Pals G, Kruyt FA, Pronk JC, Arwert F, Buchwald M, Joenje H. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:320–3.</span> [<a href="/pubmed/8896563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896563</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.lossaint.2013.678">Lossaint G, Larroque M, Ribeyre C, Bec N, Larroque C, D&#x000e9;caillet C, Gari K, Constantinou A. FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. <span><span class="ref-journal">Mol Cell. </span>2013;<span class="ref-vol">51</span>:678–90.</span> [<a href="/pubmed/23993743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23993743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mackay.2010.65">MacKay C, D&#x000e9;clais AC, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, Hofmann K, Gartner A, West SC, Helleday T, Lilley DM, Rouse J. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. <span><span class="ref-journal">Cell. </span>2010;<span class="ref-vol">142</span>:65–76.</span> [<a href="/pmc/articles/PMC3710700/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3710700</span></a>] [<a href="/pubmed/20603015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20603015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.macmillan.2015.3798">MacMillan ML, DeFor TE, Young JA, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE. Alternative donor hematopoietic cell transplantation for Fanconi anemia. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">125</span>:3798–804.</span> [<a href="/pmc/articles/PMC4463740/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4463740</span></a>] [<a href="/pubmed/25824692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25824692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.macmillan.2010.14">MacMillan ML, Wagner JE. Haematopoeitic cell transplantation for Fanconi anaemia - when and how? <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">149</span>:14–21.</span> [<a href="/pubmed/20136826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20136826</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.machida.2006.589">Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD, Dutta A. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. <span><span class="ref-journal">Mol Cell. </span>2006;<span class="ref-vol">23</span>:589–96.</span> [<a href="/pubmed/16916645" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16916645</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.magron.2015.e0140612">Magron A, Elowe S, Carreau M. The Fanconi Anemia C Protein Binds to and Regulates Stathmin-1 Phosphorylation. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0140612.</span> [<a href="/pmc/articles/PMC4605623/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4605623</span></a>] [<a href="/pubmed/26466335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26466335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.marsit.2004.1000">Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. <span><span class="ref-journal">Oncogene. </span>2004;<span class="ref-vol">23</span>:1000–4.</span> [<a href="/pubmed/14647419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14647419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.masserot.2008.3315">Masserot C, Peffault de Latour R, Rocha V, Leblanc T, Rigolet A, Pascal F, Janin A, Soulier J, Gluckman E, Soci&#x000e9; G. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. <span><span class="ref-journal">Cancer. </span>2008;<span class="ref-vol">113</span>:3315–22.</span> [<a href="/pubmed/18831513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18831513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.matsushita.2005.841">Matsushita N, Kitao H, Ishiai M, Nagashima N, Hirano S, Okawa K, Ohta T, Yu DS, McHugh PJ, Hickson ID, Venkitaraman AR, Kurumizaka H, Takata M. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. <span><span class="ref-journal">Mol Cell. </span>2005;<span class="ref-vol">19</span>:841–7.</span> [<a href="/pubmed/16168378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16168378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mccauley.2011.2370">McCauley J, Masand N, McGowan R, Rajagopalan S, Hunter A, Michaud JL, Gibson K, Robertson J, Vaz F, Abbs S, Holden ST. X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations. <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:2370–80.</span> [<a href="/pubmed/21910217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21910217</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.meetei.2003a.165">Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang W. A novel ubiquitin ligase is deficient in Fanconi anemia. <span><span class="ref-journal">Nat Genet. </span>2003a;<span class="ref-vol">35</span>:165–70.</span> [<a href="/pubmed/12973351" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12973351</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.meetei.2004.1219">Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, Rooimans MA, Bier P, Hoatlin M, Pals G, de Winter JP, Wang W, Joenje H. X-linked inheritance of Fanconi anemia complementation group B. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:1219–24.</span> [<a href="/pubmed/15502827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15502827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.meetei.2005.958">Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, Hoatlin M, Joenje H, de Winter JP, Wang W. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:958–63.</span> [<a href="/pmc/articles/PMC2704909/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2704909</span></a>] [<a href="/pubmed/16116422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.meetei.2003b.3417">Meetei AR, Sechi S, Wallisch M, Yang D, Young MK, Joenje H, Hoatlin ME, Wang W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. <span><span class="ref-journal">Mol Cell Biol. </span>2003b;<span class="ref-vol">23</span>:3417–26.</span> [<a href="/pmc/articles/PMC164758/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC164758</span></a>] [<a href="/pubmed/12724401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12724401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mehta.2017.2308">Mehta PA, Davies SM, Leemhuis T, Myers K, Kernan NA, Prockop SE, Scaradavou A, O'Reilly RJ, Williams DA, Lehmann L, Guinan E, Margolis D, Baker KS, Lane A, Boulad F. Radiation-free, alternative donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. <span><span class="ref-journal">Blood. </span>2017;<span class="ref-vol">129</span>:2308–15.</span> [<a href="/pmc/articles/PMC5766838/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5766838</span></a>] [<a href="/pubmed/28179273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28179273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mehta.2010.180">Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome&#x02014;acute myeloid leukemia in patients with Fanconi anemia. <span><span class="ref-journal">Cancer Genet Cytogenet. </span>2010;<span class="ref-vol">203</span>:180–6.</span> [<a href="/pubmed/21156231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21156231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mehta.2007.668">Mehta PA, Ileri T, Harris RE, Williams DA, Mo J, Smolarek T, Auerbach AD, Kelly P, Davies SM. Chemotherapy for myeloid malignancy in children with Fanconi anemia. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2007;<span class="ref-vol">48</span>:668–72.</span> [<a href="/pubmed/16609946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16609946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.meindl.2010.410">Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, M&#x000fc;ller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:410–4.</span> [<a href="/pubmed/20400964" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20400964</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.mi.2004.8576">Mi J, Qiao F, Wilson JB, High AA, Schroeder MJ, Stukenberg PT, Moss A, Shabanowitz J, Hunt DF, Jones NJ, Kupfer GM. FANCG is phosphorylated at serines 383 and 387 during mitosis. <span><span class="ref-journal">Mol Cell Biol. </span>2004;<span class="ref-vol">24</span>:8576–85.</span> [<a href="/pmc/articles/PMC516759/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC516759</span></a>] [<a href="/pubmed/15367677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15367677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.montes_de_oca.2005.1003">Montes de Oca R, Andreassen PR, Margossian SP, Gregory RC, Taniguchi T, Wang X, Houghtaling S, Grompe M, D'Andrea AD. Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:1003–9.</span> [<a href="/pubmed/15454491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15454491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.morgan.1999.1330">Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">65</span>:1330–41.</span> [<a href="/pmc/articles/PMC1288285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288285</span></a>] [<a href="/pubmed/10521298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10521298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.morris.2011.739">Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span>:739–46.</span> [<a href="/pmc/articles/PMC3056657/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3056657</span></a>] [<a href="/pubmed/21189382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21189382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.moynahan.2001.263">Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. <span><span class="ref-journal">Mol Cell. </span>2001;<span class="ref-vol">7</span>:263–72.</span> [<a href="/pubmed/11239455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11239455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.myers.2012.462">Myers K, Davies SM, Harris RE, Spunt SL, Smolarek T, Zimmerman S, McMasters R, Wagner L, Mueller R, Auerbach AD, Mehta PA. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2012;<span class="ref-vol">58</span>:462–5.</span> [<a href="/pubmed/21548014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21548014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nabhan.2010.1783">Nabhan SK, Bitencourt MA, Duval M, Abecasis M, Dufour C, Boudjedir K, Rocha V, Soci&#x000e9; G, Passweg J, Goi K, Sanders J, Snowden J, Yabe H, Pasquini R, Gluckman E., Aplastic Anaemia Working Party, EBMT.  Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:1783–7.</span> [<a href="/pmc/articles/PMC2948106/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2948106</span></a>] [<a href="/pubmed/20494929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20494929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nakanishi.2011.500">Nakanishi K, Cavallo F, Perrouault L, Giovannangeli C, Moynahan ME, Barchi M, Brunet E, Jasin M. Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2011;<span class="ref-vol">18</span>:500–3.</span> [<a href="/pmc/articles/PMC3273992/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3273992</span></a>] [<a href="/pubmed/21423196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21423196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nakanishi.2002.913">Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M, Mathew CG, Kastan MB, Weaver DT, D'Andrea AD. Interaction of FANCD2 and NBS1 in the DNA damage response. <span><span class="ref-journal">Nat Cell Biol. </span>2002;<span class="ref-vol">4</span>:913–20.</span> [<a href="/pubmed/12447395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12447395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.narayan.2004.2994">Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, D&#x000fc;rst M, Pothuri B, Murty VV. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. <span><span class="ref-journal">Cancer Res. </span>2004;<span class="ref-vol">64</span>:2994–7.</span> [<a href="/pubmed/15126331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15126331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.neitzel.2007">Neitzel H, K&#x000fc;hl JS, Gerlach A, Ebell W, T&#x000f6;nnies H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: results and implications. In: Schindler D, Hoehn H, eds. <em>Fanconi Anemia. a Paradigmatic Disease for the Understanding of Cancer and Aging</em>. Monographs in Human Genetics. Vol 15. Basel: Karger. 2007:79-94.</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.neveling.2009.73">Neveling K, Endt D, Hoehn H, Schindler D. Genotype&#x02013;phenotype correlations in Fanconi anemia. <span><span class="ref-journal">Mutat Res. </span>2009;<span class="ref-vol">668</span>:73–91.</span> [<a href="/pubmed/19464302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19464302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nicchia.2015.1003">Nicchia E, Benedicenti F, De Rocco D, Greco C, Bottega R, Inzana F, Faleschini M, Bonin S, Cappelli E, Mogni M, Stanzial F, Svahn J, Dufour C, Savoia A. Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing. <span><span class="ref-journal">Birth Defects Res A Clin Mol Teratol. </span>2015;<span class="ref-vol">103</span>:1003–10.</span> [<a href="/pubmed/26033879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26033879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nijman.2005.331">Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. <span><span class="ref-journal">Mol Cell. </span>2005;<span class="ref-vol">17</span>:331–9.</span> [<a href="/pubmed/15694335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15694335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.nookala.2007.1638">Nookala RK, Hussain S, Pellegrini L. Insights into Fanconi Anaemia from the structure of human FANCE. <span><span class="ref-journal">Nucleic Acids Res. </span>2007;<span class="ref-vol">35</span>:1638–48.</span> [<a href="/pmc/articles/PMC1865054/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1865054</span></a>] [<a href="/pubmed/17308347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17308347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.oda.2007.5016">Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:5016–26.</span> [<a href="/pubmed/17327415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17327415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.oestergaard.2007.798">Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, Ohzeki M, Takata M, Sale JE, Patel KJ. Deubiquitination of FANCD2 is required for DNA crosslink repair. <span><span class="ref-journal">Mol Cell. </span>2007;<span class="ref-vol">28</span>:798–809.</span> [<a href="/pmc/articles/PMC2148256/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2148256</span></a>] [<a href="/pubmed/18082605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18082605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.olopade.2003.417">Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. <span><span class="ref-journal">Cancer Cell. </span>2003;<span class="ref-vol">3</span>:417–20.</span> [<a href="/pubmed/12781358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12781358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.osorio.2013.1615">Osorio A, Bogliolo M, Fern&#x000e1;ndez V, Barroso A, de la Hoya M, Cald&#x000e9;s T, Lasa A, Ram&#x000f3;n y Cajal T, Santamari&#x000f1;a M, Vega A, Quiles F, L&#x000e1;zaro C, D&#x000ed;ez O, Fern&#x000e1;ndez D, Gonz&#x000e1;lez-Sarmiento R, Dur&#x000e1;n M, Piqueras JF, Mar&#x000ed;n M, Pujol R, Surrall&#x000e9;s J, Ben&#x000ed;tez J. Evaluation of rare variants in the new fanconi anemia gene ERCC4 (FANCQ) as familial breast/ovarian cancer susceptibility alleles. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:1615–8.</span> [<a href="/pubmed/24027083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24027083</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.pace.2002.3414">Pace P, Johnson M, Tan WM, Mosedale G, Sng C, Hoatlin M, de Winter J, Joenje H, Gergely F, Patel KJ. FANCE: the link between Fanconi anaemia complex assembly and activity. <span><span class="ref-journal">EMBO J. </span>2002;<span class="ref-vol">21</span>:3414–23.</span> [<a href="/pmc/articles/PMC125396/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC125396</span></a>] [<a href="/pubmed/12093742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12093742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.pang.2000.4724">Pang Q, Fagerlie S, Christianson TA, Keeble W, Faulkner G, Diaz J, Rathbun RK, Bagby GC. The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. <span><span class="ref-journal">Mol Cell Biol. </span>2000;<span class="ref-vol">20</span>:4724–35.</span> [<a href="/pmc/articles/PMC85895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC85895</span></a>] [<a href="/pubmed/10848598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10848598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.park.2016.672">Park JY, Virts EL, Jankowska A, Wiek C, Othman M, Chakraborty SC, Vance GH, Alkuraya FS, Hanenberg H, Andreassen PR. Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene. <span><span class="ref-journal">J Med Genet. </span>2016;<span class="ref-vol">53</span>:672–80.</span> [<a href="/pmc/articles/PMC5035190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5035190</span></a>] [<a href="/pubmed/27208205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27208205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.parmar.2010.1186">Parmar K, Kim J, Sykes SM, Shimamura A, Stuckert P, Zhu K, Hamilton A, Deloach MK, Kutok JL, Akashi K, Gilliland DG, D'andrea A. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. <span><span class="ref-journal">Stem Cells. </span>2010;<span class="ref-vol">28</span>:1186–95.</span> [<a href="/pmc/articles/PMC2910804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2910804</span></a>] [<a href="/pubmed/20506303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20506303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.pichierri.2004.1178">Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. <span><span class="ref-journal">EMBO J. </span>2004;<span class="ref-vol">23</span>:1178–87.</span> [<a href="/pmc/articles/PMC380971/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC380971</span></a>] [<a href="/pubmed/14988723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14988723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.polito.2014.7003">Polito D, Cukras S, Wang X, Spence P, Moreau L, D'Andrea AD, Kee Y. The carboxyl terminus of FANCE recruits FANCD2 to the Fanconi anemia (FA) E3 ligase complex to promote the FA DNA repair pathway. <span><span class="ref-journal">J Biol Chem. </span>2014;<span class="ref-vol">289</span>:7003–10.</span> [<a href="/pmc/articles/PMC3945361/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3945361</span></a>] [<a href="/pubmed/24451376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24451376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.qiao.2004.46035">Qiao F, Mi J, Wilson JB, Zhi G, Bucheimer NR, Jones NJ, Kupfer GM. Phosphorylation of Fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:46035–45.</span> [<a href="/pubmed/15299017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15299017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rafnar.2011.1104">Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, Orlygsdottir G, Helgadottir HT, Johannsdottir H, Gylfason A, Tryggvadottir L, Jonasson JG, de Juan A, Ortega E, Ramon-Cajal JM, Garc&#x000ed;a-Prats MD, Mayordomo C, Panadero A, Rivera F, Aben KK, van Altena AM, Massuger LF, Aavikko M, Kujala PM, Staff S, Aaltonen LA, Olafsdottir K, Bjornsson J, Kong A, Salvarsdottir A, Saemundsson H, Olafsson K, Benediktsdottir KR, Gulcher J, Masson G, Kiemeney LA, Mayordomo JI, Thorsteinsdottir U, Stefansson K. Mutations in BRIP1 confer high risk of ovarian cancer. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:1104–7.</span> [<a href="/pubmed/21964575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21964575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rahman.2007.165">Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D. Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:165–7.</span> [<a href="/pmc/articles/PMC2871593/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2871593</span></a>] [<a href="/pubmed/17200668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17200668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rajendra.2014.858">Rajendra E, Oestergaard VH, Langevin F, Wang M, Dornan GL, Patel KJ, Passmore LA. The genetic and biochemical basis of FANCD2 monoubiquitination. <span><span class="ref-journal">Mol Cell. </span>2014;<span class="ref-vol">54</span>:858–69.</span> [<a href="/pmc/articles/PMC4051986/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4051986</span></a>] [<a href="/pubmed/24905007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24905007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.reid.2007.162">Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:162–4.</span> [<a href="/pubmed/17200671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17200671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rickman.2015.35">Rickman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O, Chandrasekharappa SC, Schindler D, Auerbach AD, Smogorzewska A. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia. <span><span class="ref-journal">Cell Rep. </span>2015;<span class="ref-vol">12</span>:35–41.</span> [<a href="/pmc/articles/PMC4497947/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4497947</span></a>] [<a href="/pubmed/26119737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26119737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rose.2014.11">Rose SR, Kim MO, Korbee L, Wilson KA, Douglas Ris M, Eyal O, Sherafat-Kazemzadeh R, Bollepalli S, Harris R, Jeng MR, Williams DA, Smith FO. Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2014;<span class="ref-vol">61</span>:11–9.</span> [<a href="/pubmed/24019220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24019220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rosenberg.2008.511">Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. <span><span class="ref-journal">Haematologica. </span>2008;<span class="ref-vol">93</span>:511–7.</span> [<a href="/pubmed/18322251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18322251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rosenberg.2005.67">Rosenberg PS, Soci&#x000e9; G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:67–73.</span> [<a href="/pubmed/15331448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15331448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.rosenberg.2011.1877">Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:1877–83.</span> [<a href="/pmc/articles/PMC3140593/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3140593</span></a>] [<a href="/pubmed/21739583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21739583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.sarkies.2012.1485">Sarkies P, Murat P, Phillips LG, Patel KJ, Balasubramanian S, Sale JE. FANCJ coordinates two pathways that maintain epigenetic stability at G-quadruplex DNA. <span><span class="ref-journal">Nucleic Acids Res. </span>2012;<span class="ref-vol">40</span>:1485–98.</span> [<a href="/pmc/articles/PMC3287192/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3287192</span></a>] [<a href="/pubmed/22021381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22021381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.sato.2012.4553">Sato K, Toda K, Ishiai M, Takata M, Kurumizaka H. DNA robustly stimulates FANCD2 monoubiquitylation in the complex with FANCI. <span><span class="ref-journal">Nucleic Acids Res. </span>2012;<span class="ref-vol">40</span>:4553–61.</span> [<a href="/pmc/articles/PMC3378891/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3378891</span></a>] [<a href="/pubmed/22287633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22287633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.sawyer.2015.135">Sawyer SL, Tian L, K&#x000e4;hk&#x000f6;nen M, Schwartzentruber J, Kircher M, et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. <span><span class="ref-journal">Cancer Discov. </span>2015;<span class="ref-vol">5</span>:135–42.</span> [<a href="/pmc/articles/PMC4320660/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4320660</span></a>] [<a href="/pubmed/25472942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25472942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.scheckenbach.2012.128">Scheckenbach K, Morgan M, Filger-Brillinger J, Sandmann M, Strimling B, Scheurlen W, Schindler D, Gobel U, Hanenberg H. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2012;<span class="ref-vol">48</span>:128–131.</span> [<a href="/pubmed/22178060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22178060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.seal.2006.1239">Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:1239–41.</span> [<a href="/pubmed/17033622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17033622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.shimamura.2010.101">Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. <span><span class="ref-journal">Blood Rev. </span>2010;<span class="ref-vol">24</span>:101–22.</span> [<a href="/pmc/articles/PMC3733544/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3733544</span></a>] [<a href="/pubmed/20417588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20417588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.singh.2009.174">Singh TR, Bakker ST, Agarwal S, Jansen M, Grassman E, Godthelp BC, Ali AM, Du CH, Rooimans MA, Fan Q, Wahengbam K, Steltenpool J, Andreassen PR, Williams DA, Joenje H, de Winter JP, Meetei AR. Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>:174–80.</span> [<a href="/pmc/articles/PMC2710946/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2710946</span></a>] [<a href="/pubmed/19423727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19423727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.smogorzewska.2010.36">Smogorzewska A, Desetty R, Saito TT, Schlabach M, Lach FP, Sowa ME, Clark AB, Kunkel TA, Harper JW, Colai&#x000e1;covo MP, Elledge SJ. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. <span><span class="ref-journal">Mol Cell. </span>2010;<span class="ref-vol">39</span>:36–47.</span> [<a href="/pmc/articles/PMC2919743/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2919743</span></a>] [<a href="/pubmed/20603073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20603073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.smogorzewska.2007.289">Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER 3rd, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. <span><span class="ref-journal">Cell. </span>2007;<span class="ref-vol">129</span>:289–301.</span> [<a href="/pmc/articles/PMC2175179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2175179</span></a>] [<a href="/pubmed/17412408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17412408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.sommers.2014.19928">Sommers JA, Banerjee T, Hinds T, Wan B, Wold MS, Lei M, Brosh RM Jr. Novel function of the Fanconi anemia group J or RECQ1 helicase to disrupt protein-DNA complexes in a replication protein A-stimulated manner. <span><span class="ref-journal">J Biol Chem. </span>2014;<span class="ref-vol">289</span>:19928–41.</span> [<a href="/pmc/articles/PMC4106313/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4106313</span></a>] [<a href="/pubmed/24895130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24895130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.song.2010.31525">Song IY, Palle K, Gurkar A, Tateishi S, Kupfer GM, Vaziri C. Rad18-mediated translesion synthesis of bulky DNA adducts is coupled to activation of the Fanconi anemia DNA repair pathway. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:31525–36.</span> [<a href="/pmc/articles/PMC2951227/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2951227</span></a>] [<a href="/pubmed/20675655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20675655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.spanier.2012.510">Spanier G, Pohl F, Giese T, Meier JK, Koelbl O, Reichert TE. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: a mini review. <span><span class="ref-journal">J Craniomaxillofac Surg. </span>2012;<span class="ref-vol">40</span>:510–5.</span> [<a href="/pubmed/21925890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21925890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.stoepker.2011.138">Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, Oostra AB, Eirich K, Korthof ET, Nieuwint AW, Jaspers NG, Bettecken T, Joenje H, Schindler D, Rouse J, de Winter JP. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:138–41.</span> [<a href="/pubmed/21240277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21240277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.talbot.2014.e199">Talbot A, Peffault de Latour R, Raffoux E, Buchbinder N, Vigouroux S, Milpied N, Leblanc T, Soulier J, Michallet M, Soci&#x000e9; G. Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia. <span><span class="ref-journal">Haematologica. </span>2014;<span class="ref-vol">99</span>:e199–200.</span> [<a href="/pmc/articles/PMC4181270/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4181270</span></a>] [<a href="/pubmed/25085358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25085358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.tamary.2010.1300">Tamary H, Nishri D, Yacobovich J, Zilber R, Dgany O, Krasnov T, Aviner S, Stepensky P, Ravel-Vilk S, Bitan M, Kaplinsky C, Ben Barak A, Elhasid R, Kapelusnik J, Koren A, Levin C, Attias D, Laor R, Yaniv I, Rosenberg PS, Alter BP. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry. <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:1300–7.</span> [<a href="/pmc/articles/PMC2913078/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2913078</span></a>] [<a href="/pubmed/20435624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20435624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.tan.2011.e591">Tan IB, Cutcutache I, Zang ZJ, Iqbal J, Yap SF, Hwang W, Lim WT, Teh BT, Rozen S, Tan EH, Tan P. Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. <span><span class="ref-journal">J Clin Oncol. </span>2011;<span class="ref-vol">29</span>:e591–4.</span> [<a href="/pubmed/21519011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21519011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.taniguchi.2006.4223">Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:4223–33.</span> [<a href="/pubmed/16493006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16493006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.taniguchi.2002a.2414">Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. <span><span class="ref-journal">Blood. </span>2002a;<span class="ref-vol">100</span>:2414–20.</span> [<a href="/pubmed/12239151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12239151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.taniguchi.2002b.459">Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB, D'Andrea AD. Convergence of the Fanconi anemia and ataxia-telangiectasia signaling pathways. <span><span class="ref-journal">Cell. </span>2002b;<span class="ref-vol">109</span>:459–72.</span> [<a href="/pubmed/12086603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12086603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.taniguchi.2003.568">Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. <span><span class="ref-journal">Nat Med. </span>2003;<span class="ref-vol">9</span>:568–74.</span> [<a href="/pubmed/12692539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12692539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.tischkowitz.2007.6788">Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN-associated breast cancer families. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007;<span class="ref-vol">104</span>:6788–93.</span> [<a href="/pmc/articles/PMC1871863/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1871863</span></a>] [<a href="/pubmed/17420451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17420451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.tolar.2011.1193">Tolar J, Adair JE, Antoniou M, Bartholomae CC, Becker PS, Blazar BR, Bueren J, Carroll T, Cavazzana-Calvo M, Clapp DW, Dalgleish R, Galy A, Gaspar HB, Hanenberg H, Von Kalle C, Kiem HP, Lindeman D, Naldini L, Navarro S, Renella R, Rio P, Sevilla J, Schmidt M, Verhoeyen E, Wagner JE, Williams DA, Thrasher AJ. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:1193–8.</span> [<a href="/pmc/articles/PMC3129570/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3129570</span></a>] [<a href="/pubmed/21540837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21540837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.turner.2004.814">Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. <span><span class="ref-journal">Nat Rev Cancer. </span>2004;<span class="ref-vol">4</span>:814–9.</span> [<a href="/pubmed/15510162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15510162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.uma_a.2011.3071">Uma&#x000f1;a LA, Magoulas P, Bi W, Bacino CA. A male newborn with VACTERL association and Fanconi anemia with a FANCB deletion detected by array comparative genomic hybridization (aCGH). <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:3071–4.</span> [<a href="/pubmed/22052692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22052692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.van_der_heijden.2003.2585">van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. <span><span class="ref-journal">Cancer Res. </span>2003;<span class="ref-vol">63</span>:2585–8.</span> [<a href="/pubmed/12750283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12750283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.vandenberg.2003.247">Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, Hiom K, Patel KJ. BRCA1-independent ubiquitination of FANCD2. <span><span class="ref-journal">Mol Cell. </span>2003;<span class="ref-vol">12</span>:247–54.</span> [<a href="/pubmed/12887909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12887909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.vaz.2010.406">Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:406–9.</span> [<a href="/pubmed/20400963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20400963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.vetro.2015.562">Vetro A, Iascone M, Limongelli I, Ameziane N, Gana S, Della Mina E, Giussani U, Ciccone R, Forlino A, Pezzoli L, Rooimans MA, van Essen AJ, Messa J, Rizzuti T, Bianchi P, Dorsman J, de Winter JP, Lalatta F, Zuffardi O. Loss-of-function FANCL mutations associate with severe Fanconi anemia overlapping the VACTERL association. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:562–8.</span> [<a href="/pubmed/25754594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.virts.2015.5093">Virts EL, Jankowska A, Mackay C, Glaas MF, Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehnert E, Scharf RE, Dufour C, Lanciotti M, Farruggia P, Santoro A, Savasan S, Scheckenbach K, Schipper J, Wagenmann M, Lewis T, Leffak M, Farlow JL, Foroud TM, Honisch E, Niederacher D, Chakraborty SC, Vance GH, Pruss D, Timms KM, Lanchbury JS, Alpi AF, Hanenberg H. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. <span><span class="ref-journal">Hum Mol Genet. </span>2015;<span class="ref-vol">24</span>:5093–108.</span> [<a href="/pmc/articles/PMC4550815/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4550815</span></a>] [<a href="/pubmed/26085575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26085575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wagner.2004.3226">Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, Ben-Porat L, Mah K, Batish SD, Kutler DI, MacMillan ML, Hanenberg H, Auerbach AD. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:3226–9.</span> [<a href="/pubmed/15070707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15070707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wang.2015.354">Wang AT, Smogorzewska A. SnapShot: Fanconi anemia and associated proteins. <span><span class="ref-journal">Cell. </span>2015;<span class="ref-vol">160</span>:354–354.e1.</span> [<a href="/pubmed/25594185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25594185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wang.2004.5850">Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. <span><span class="ref-journal">Mol Cell Biol. </span>2004;<span class="ref-vol">24</span>:5850–62.</span> [<a href="/pmc/articles/PMC480901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC480901</span></a>] [<a href="/pubmed/15199141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15199141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wang.2007.3098">Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. <span><span class="ref-journal">Mol Cell Biol. </span>2007;<span class="ref-vol">27</span>:3098–108.</span> [<a href="/pmc/articles/PMC1899922/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1899922</span></a>] [<a href="/pubmed/17296736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17296736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wang.2006.256">Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. <span><span class="ref-journal">Cancer Biol Ther. </span>2006;<span class="ref-vol">5</span>:256–60.</span> [<a href="/pubmed/16418574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16418574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wang.2015.478">Wang AT, Kim T, Wagner JE, Conti BA, Lach FP, Huang AL, Molina H, Sanborn EM, Zierhut H, Cornes BK, Abhyankar A, Sougnez C, Gabriel SB, Auerbach AD, Kowalczykowski SC, Smogorzewska A. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. <span><span class="ref-journal">Mol Cell. </span>2015;<span class="ref-vol">59</span>:478–90.</span> [<a href="/pmc/articles/PMC4529964/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4529964</span></a>] [<a href="/pubmed/26253028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26253028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.whitney.1993.202">Whitney MA, Saito H, Jakobs PM, Gibson RA, Moses RE, Grompe M. A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. <span><span class="ref-journal">Nat Genet. </span>1993;<span class="ref-vol">4</span>:202–5.</span> [<a href="/pubmed/8348157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8348157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wijker.1999.52">Wijker M, Morgan NV, Herterich S, van Berkel CG, Tipping AJ, Gross HJ, Gille JJ, Pals G, Savino M, Altay C, Mohan S, Dokal I, Cavenagh J, Marsh J, van Weel M, Ortega JJ, Schuler D, Samochatova E, Karwacki M, Bekassy AN, Abecasis M, Ebell W, Kwee ML, de Ravel T, Mathew CG. Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene. <span><span class="ref-journal">Eur J Hum Genet. </span>1999;<span class="ref-vol">7</span>:52–9.</span> [<a href="/pubmed/10094191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10094191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.williams.2011a.5078">Williams SA, Longerich S, Sung P, Vaziri C, Kupfer GM. The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI. <span><span class="ref-journal">Blood. </span>2011a;<span class="ref-vol">117</span>:5078–87.</span> [<a href="/pmc/articles/PMC3109534/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3109534</span></a>] [<a href="/pubmed/21355096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21355096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.williams.2011b.4395">Williams SA, Wilson JB, Clark AP, Mitson-Salazar A, Tomashevski A, Ananth S, Glazer PM, Semmes OJ, Bale AE, Jones NJ, Kupfer GM. Functional and physical interaction between the mismatch repair and FA-BRCA pathways. <span><span class="ref-journal">Hum Mol Genet. </span>2011b;<span class="ref-vol">20</span>:4395–410.</span> [<a href="/pmc/articles/PMC3196888/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3196888</span></a>] [<a href="/pubmed/21865299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21865299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wilson.2010.12">Wilson JB, Blom E, Cunningham R, Xiao Y, Kupfer GM, Jones NJ. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. <span><span class="ref-journal">Mutat Res. </span>2010;<span class="ref-vol">689</span>:12–20.</span> [<a href="/pmc/articles/PMC2903733/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2903733</span></a>] [<a href="/pubmed/20450923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20450923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wong.2003.2063">Wong JC, Alon N, McKerlie C, Huang JR, Meyn MS, Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:2063–76.</span> [<a href="/pubmed/12913077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12913077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wu.2009.470">Wu Y, Brosh RM Jr. FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. <span><span class="ref-journal">Curr Mol Med. </span>2009;<span class="ref-vol">9</span>:470–82.</span> [<a href="/pmc/articles/PMC2763586/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2763586</span></a>] [<a href="/pubmed/19519404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19519404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.wu.2012.21699">Wu Y, Sommers JA, Loiland JA, Kitao H, Kuper J, Kisker C, Brosh RM Jr. The Q motif of Fanconi anemia group J protein (FANCJ) DNA helicase regulates its dimerization, DNA binding, and DNA repair function. <span><span class="ref-journal">J Biol Chem. </span>2012;<span class="ref-vol">287</span>:21699–716.</span> [<a href="/pmc/articles/PMC3381133/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3381133</span></a>] [<a href="/pubmed/22582397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22582397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.xia.2007.159">Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:159–61.</span> [<a href="/pubmed/17200672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17200672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.xia.2006.719">Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. <span><span class="ref-journal">Mol Cell. </span>2006;<span class="ref-vol">22</span>:719–29.</span> [<a href="/pubmed/16793542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16793542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.xie.2012.e1002786">Xie J, Peng M, Guillemette S, Quan S, Maniatis S, Wu Y, Venkatesh A, Shaffer SA, Brosh RM Jr, Cantor SB. FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage response. <span><span class="ref-journal">PLoS Genet. </span>2012;<span class="ref-vol">8</span>:e1002786.</span> [<a href="/pmc/articles/PMC3390368/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3390368</span></a>] [<a href="/pubmed/22792074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22792074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.yamashita.1994.6712">Yamashita T, Barber DL, Zhu Y, Wu N, D'Andrea AD. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1994;<span class="ref-vol">91</span>:6712–6.</span> [<a href="/pmc/articles/PMC44273/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC44273</span></a>] [<a href="/pubmed/7517562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7517562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.yamashita.1996.4424">Yamashita T, Wu N, Kupfer G, Corless C, Joenje H, Grompe M, D'Andrea AD. The Clinical variability of Fanconi Anemia (Type C) results from expression of an amino terminal truncated FAC polypeptide with partial activity. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">87</span>:4424.</span> [<a href="/pubmed/8639804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8639804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.yoshikiyo.2010.21553">Yoshikiyo K, Kratz K, Hirota K, Nishihara K, Takata M, Kurumizaka H, Horimoto S, Takeda S, Jiricny J. KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2010;<span class="ref-vol">107</span>:21553–7.</span> [<a href="/pmc/articles/PMC3003052/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3003052</span></a>] [<a href="/pubmed/21115814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21115814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zhang.2010.637">Zhang F, Fan Q, Ren K, Auerbach AD, Andreassen PR. FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. <span><span class="ref-journal">Chromosoma. </span>2010;<span class="ref-vol">119</span>:637–49.</span> [<a href="/pmc/articles/PMC4928586/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4928586</span></a>] [<a href="/pubmed/20676667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20676667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zhi.2009.8775">Zhi G, Wilson JB, Chen X, Krause DS, Xiao Y, Jones NJ, Kupfer GM. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for Fanconi anemia pathway function and BRCA2 interaction. <span><span class="ref-journal">Cancer Res. </span>2009;<span class="ref-vol">69</span>:8775–83.</span> [<a href="/pmc/articles/PMC5912675/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5912675</span></a>] [<a href="/pubmed/19861535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19861535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zhu.2015a.2867">Zhu B, Yan K, Li L, Lin M, Zhang S, He Q, Zheng D, Yang H, Shao G. K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks. <span><span class="ref-journal">Oncogene. </span>2015a;<span class="ref-vol">34</span>:2867–78.</span> [<a href="/pubmed/25132264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25132264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zhu.2015b.1809">Zhu J, Su F, Mukherjee S, Mori E, Hu B, Asaithamby A. FANCD2 influences replication fork processes and genome stability in response to clustered DSBs. <span><span class="ref-journal">Cell Cycle. </span>2015b;<span class="ref-vol">14</span>:1809–22.</span> [<a href="/pmc/articles/PMC4613663/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4613663</span></a>] [<a href="/pubmed/26083937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26083937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zou.2013.1022">Zou J, Tian F, Li J, Pickner W, Long M, Rezvani K, Wang H, Zhang D. FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. <span><span class="ref-journal">Biol Open. </span>2013;<span class="ref-vol">2</span>:1022–31.</span> [<a href="/pmc/articles/PMC3798185/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3798185</span></a>] [<a href="/pubmed/24167712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24167712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fa.REF.zou.2014.3685">Zou J, Zhang D, Qin G, Chen X, Wang H, Zhang D. BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. <span><span class="ref-journal">Cell Cycle. </span>2014;<span class="ref-vol">13</span>:3685–97.</span> [<a href="/pmc/articles/PMC4612125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4612125</span></a>] [<a href="/pubmed/25483079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25483079</span></a>]</div></li></ul></div></div><div id="fa.Chapter_Notes"><h2 id="_fa_Chapter_Notes_">Chapter Notes</h2><div id="fa.Author_Notes"><h3>Author Notes</h3><p><b>Comprehensive Center for Fanconi Anemia</b><br />Dana Farber Cancer Institute <br />Mayer 676 <br />44 Binney Street <br />Boston, MA 02115 <br />Phone: 617-632-6302</p></div><div id="fa.Author_History"><h3>Author History</h3><p>Blanche P Alter, MD, MPH, FAAP; National Cancer Institute (2011-2016)<br />Alan D'Andrea, MD; Dana Farber Cancer Institute (2002-2007) <br />Gary Kupfer, MD; Yale University School of Medicine (2011-2016)<br />Parinda A Mehta, MD (2016-present)<br />Lisa Moreau, MS; Dana Farber Cancer Institute (2002-2007) <br />Akiko Shimamura, MD, PhD; Dana Farber Cancer Institute (2002-2007) <br />Toshiyasu Taniguchi, MD, PhD; Fred Hutchinson Cancer Research Center (2007-2011)<br />Jakub Tolar, MD, PhD (2016-present)</p></div><div id="fa.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 March 2018 (aa, pm) Revision: addition of one <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>: <i>RFWD3</i></div></li><li class="half_rhythm"><div>23 February 2017 (aa, pm) Revision: addition of two genes: <i>MAD2L2</i> and <i>XRCC2</i>; edits to <a href="#fa.Prevention_of_Secondary_Complications">Prevention of Secondary Complications</a></div></li><li class="half_rhythm"><div>22 September 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 February 2013 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically for <i>FANCC</i></div></li><li class="half_rhythm"><div>6 September 2012 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> for mutations in <i>RAD51C</i> and <i>SLX4</i> available clinically</div></li><li class="half_rhythm"><div>3 November 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically for <i>PALB2</i> deletions</div></li><li class="half_rhythm"><div>10 February 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 March 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and prenatal testing available clinically for <i>FANCB-</i>, <i>FANCE</i>-, <i>FANCF</i>- and <i>FANCI</i>-related Fanconi anemia</div></li><li class="half_rhythm"><div>29 January 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of <i>FANCG</i> and prenatal testing available</div></li><li class="half_rhythm"><div>7 November 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> no longer available on a clinical basis for <i>FANCF</i> and <i>FANCG</i></div></li><li class="half_rhythm"><div>22 June 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 March 2006 (cd) Revision: <i>FANCB</i> mutations: <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</div></li><li class="half_rhythm"><div>3 January 2006 (as) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing clinically available</div></li><li class="half_rhythm"><div>13 September 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>31 May 2001 (as) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1401</span><span class="label">PMID: <a href="/pubmed/20301575" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301575</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/porphyria-ct/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fahn/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1401&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1401/?report=reader">PubReader</a></li><li><a href="/books/NBK1401/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1401" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1401" style="display:none" title="Cite this Page"><div class="bk_tt">Mehta PA, Tolar J. Fanconi Anemia. 2002 Feb 14 [Updated 2018 Mar 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1401/pdf/Bookshelf_NBK1401.pdf">PDF version of this page</a> (688K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#fa.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#fa.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#fa.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#fa.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#fa.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#fa.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#fa.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#fa.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#fa.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#fa.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#fa.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2176[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=83990[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRIP1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2177[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCD2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2072[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERCC4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2189[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCG</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2175[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCA</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2178[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCE</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2188[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCF</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=55215[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCI</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10459[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MAD2L2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2187[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=55120[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FANCL</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=55159[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RFWD3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5889[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RAD51C</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=84464[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLX4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=675[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRCA2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=79728[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PALB2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=29089[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">UBE2T</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5888[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RAD51</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7516[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">XRCC2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1401+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1471774" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1471774" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1471774" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1471774" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301769" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clinton C, Gazda HT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301722" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Shwachman-Diamond Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Shwachman-Diamond Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nelson A, Myers K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301779" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dyskeratosis Congenita</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dyskeratosis Congenita<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Savage SA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301584" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allenspach E, Rawlings DJ, Scharenberg AM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21634085" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301575" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301575" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04113175f66d18aadeaea0">Fanconi Anemia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Fanconi Anemia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:47:29-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D684DE040442100000000056B01FA&amp;ncbi_session=CE8D684DE0411301_1387SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1401%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1401&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1401/&amp;ncbi_pagename=Fanconi Anemia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D684DE0411301_1387SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>